Thrombosis and thrombocytopenia after vaccination against and infection with SARS-CoV-2: a population-based cohort analysis

Edward Burn^{1,2*}, Xintong Li^{2*}, Antonella Delmestri², Nathan Jones², Talita Duarte-Salles¹, Carlen Reyes¹, Eugenia Martinez-Hernandez³, Edelmira Marti⁴, Katia MC Verhamme⁵, Peter R Rijnbeek⁵, Victoria Y Strauss^{2†}, Daniel Prieto-Alhambra^{2,5†}

¹Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain, ²Centre for Statistics in Medicine (CSM), Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDROMS), University of Oxford, UK, ³Department of Neurology, Hospital Clinic and University of Barcelona, Barcelona, Spain, ⁴Hemostasis and Thrombosis Unit, Hematology Department, Hospital Clínico Universitario de Valencia, Spain, ⁵Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands

*Joint first authors, † Joint senior authors

Corresponding author: Prof Daniel Prieto-Alhambra, Botnar Research Centre, Windmill Road, OX37LD, Oxford, UK, daniel.prietoalhambra@ndorms.ox.ac.uk

Abstract

Objectives

To calculate the observed rates of thrombosis and thrombocytopenia following vaccination against SARS-CoV-2, infection with SARS-CoV-2, and to compare them to background (expected) rates in the general population.

Design

Cohort study using routinely collected primary care records.

Setting

Routine practice in the United Kingdom.

Participants

Two mutually exclusive vaccinated cohorts included people vaccinated with either ChAdOx1 or BNT162b2 between 8 December 2020 and 6 March 2021. A third cohort consisted of people newly infected with SARS-Cov-2 identified by a first positive RT-PCR test between 1 September 2020 and 28 February 2021. The fourth general population cohort for background rates included those people with a visit between 1 January 2017 and 31 December 2019. In total, we included 1,868,767 ChAdOx1 and 1,661,139 BNT162b2 vaccinees, 299,311 people infected with SARS-CoV-2, and 2,290,537 people from the general population.

Interventions

First-dose of either ChAdOx1 or BNT162b2

Main outcome measures

Outcomes included venous thrombosis, arterial thrombosis, thrombocytopenia, and thrombosis with thrombocytopenia. Outcome rates were estimated for recipients of the ChAdOx1 or BNT162b2 vaccines, for people infected with SARS-CoV-2, and background rates in the general population. Indirectly standardized incidence ratios (SIR) were estimated.

Results

We included 1,868,767 ChAdOx1 and 1,661,139 BNT162b2 vaccinees, 299,311 people infected with SARS-CoV-2, and 2,290,537 people from the general population for background rates. The SIRs for pulmonary embolism were 1.23 [95% CI, 1.09-1.39] after vaccination with ChAdOx1, 1.21 [1.07-1.36] after vaccination with BNT162b2, and 15.31 [14.08 to 16.65] for infection with SARS-CoV-2. The SIRs for thrombocytopenia after vaccination were 1.25 [1.19 to 1.31] for ChAdOx1 and 0.99 (0.94 to 1.04) for BNT162b2. Rates of deep vein thrombosis and arterial thrombosis were similar among those vaccinated and the general population.

Conclusions

ChAdOx1 and BNT162b2 had broadly similar safety profiles. Thrombosis rates after either vaccine were mostly similar to those of the general population. Rates of pulmonary embolism increased 1.2-fold after either vaccine and 15-fold with SARS-CoV-2 infection. Thrombocytopenia was more common among recipients of ChAdOx1 but not of BNT162b2.

Summary box

What is already known on this topic

- Spontaneous reports of unusual and severe thrombosis with thrombocytopenia syndrome (TTS) raised concerns regarding the safety of adenovirus-based vaccines against SARS-CoV-2
- In a cohort study including over 280,000 people aged 18-65 years vaccinated with ChAdOx1 in Denmark and Norway, Pottegård et al reported increased rates of venous thromboembolic events as well as thrombocytopenia among vaccine recipients.

What this study adds

- In this cohort study, ChAdOx1 and BNT162b2 were seen to have broadly similar safety profiles.
- Rates of thrombosis after either vaccine were generally similar to those of the general population. Rates of pulmonary embolism were though 1.2-fold higher than background rates after either vaccine, which compared to 15-fold higher after SARS-CoV-2 infection.
- Thrombocytopenia was more common among recipients of ChAdOx1 but not of BNT162b2.

Introduction

Vaccines against SARS-CoV-2 have been developed rapidly using a number of platforms. The ChAdOx1 nCoV-19 (Oxford–AstraZeneca; ChAdOx1) and BNT162b2 mRNA (Pfizer–BioNTech; BNT162b2) vaccines received approval for use in the United Kingdom on 8 and 31 December 2020, respectively. Evidence from clinical trials and real-world data has shown these vaccines to be highly effective in preventing symptomatic COVID-19, severe disease, and hospitalization.^{1–7}

As COVID-19 vaccines have been approved under emergency authorization, they must continue to be monitored to assess their safety. Instances of rare adverse events have been identified alongside the ongoing nationwide immunization programs.^{8–10} A particular concern has arisen regarding thrombotic events, with concurrent thrombocytopenia reported among individuals vaccinated with adenovirus-based vaccines against SARS-CoV-2. As of 26 May 2021, 348 spontaneous reports of major thromboembolic events with thrombocytopenia had been documented following 24 million first doses and 13 million second doses of the ChAdOx1 vaccine in the UK.¹¹ Although fewer concerns have been raised about safety signals for BNT162b2, instances of immune thrombocytopenia have also been observed among recipients of this vaccine.¹²

In this study, we estimated the incidence of thrombosis, thrombocytopenia, and thrombosis with thrombocytopenia over the 28 days following a first dose of the ChAdOx1 and BNT162b2 vaccines and compared these rates with historical, pre-pandemic rates in the general population. To provide additional context, we also studied the rates of these events after a positive RT-PCR test for SARS-CoV-2.

Methods

Study design, setting, and data sources

People vaccinated against SARS-CoV-2 and people infected with SARS-CoV-2 were identified from Clinical Practice Research Datalink (CPRD) AURUM. A background cohort was obtained from CPRD GOLD to estimate pre-pandemic background rates. AURUM and GOLD are established primary care databases broadly representative of the UK population,^{13,14} and previous research has demonstrated their validity for vaccine safety surveillance.^{15,16} Both databases were mapped to the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) for analysis.¹⁷

Study participants and follow-up

Four cohorts were studied. Two mutually exclusive vaccinated cohorts included people vaccinated with either ChAdOx1 or BNT162b2 between 8 December 2020 and 6 March 2021. They were followed for up to 28 days from their first vaccination (index date). A third cohort consisted of people newly infected with SARS-Cov-2 identified by a first positive RT-PCR test between 1 September 2020 and 28 February 2021. The test date was used as the index date. They were followed for up to 90 days. The fourth cohort, a general population background cohort, included people who had a primary care visit or contact recorded between 1 January 2017 and 31 December 2019. That first visit or contact was used as the index date and follow-up ran up to 31 December 2019.

All participants were required to be aged 30 years or older and, for the primary analysis, have at least 1 year of prior history available. Participants did not contribute to an analysis if they had the same event recorded in the year before their index date. Time at risk was censored if an individual had the outcome of interest or exited the database before the end of follow-up.

Sensitivity analyses were conducted removing the requirements of a year of prior history and, for the background population, a primary care visit or contact. For the latter, 1 January 2017 was used as the index date.

Study outcomes

We used diagnostic codes to identify five venous thromboembolic events: cerebral venous sinus thrombosis (CVST), deep vein thrombosis (DVT), pulmonary embolism (PE), splanchnic vein thrombosis (SVT), and the composite event venous thromboembolism (VTE), which encompassed DVT and PE. We identified two arterial thromboembolic events (ATE): myocardial infarction and ischemic stroke. We also used an overall stroke definition that included non-specific, hemorrhagic, and ischemic stroke codes.

Thrombocytopenia was identified using diagnostic codes and laboratory data showing platelets count between 10,000 and 150,000 platelets per microliter, based on the Brighton collaboration definition.¹⁸ Immune thrombocytopenia was identified using diagnostic codes.

Thrombosis with thrombocytopenia syndromes (TTS) was identified where thrombocytopenia was observed within 10 days before or after thrombosis. This time window was broadened in a sensitivity analysis.

Results for additional related outcomes (intestinal infarction, platelet disorder, portal vein thrombosis, and thrombocytopenic purpura) are reported in the Appendix.

Statistical methods

For each cohort and outcome of interest, we describe the cohort's age, sex, comorbidities, and medication use within 6 months before and up to 4 days before the index date. We report the number of events observed and crude incidence rates per 100,000 person-years with 95% confidence intervals (CIs). We used indirect standardization with the background cohort as the standard to estimate the number of events expected for the vaccination and SARS-CoV-2 cohorts if their risk was the same as that of the general population.¹⁹ We estimated standardized incidence ratios (SIRs) and 95% confidence intervals comparing observed and expected rates. We stratified all analyses by 10-year age bands and sex and analyses of those vaccinated by calendar month. We calculated the standardized event difference proportion to provide a measure of absolute risk. To avoid re-identification, we do not report any analysis with under 5 cases.

The study protocol was published in the EU PAS Register (EUPAS40414). The use of CPRD data was approved by the Independent Scientific Advisory Committee (21_000391 and 20_000211). All analytical code is available at: <https://github.com/oxford-pharmacoepi/CovidVaccinationSafetyStudy>.

Patient and public involvement

No patients or members of the public were directly involved in the study design or its execution.

Results

We included 1,868,767 people vaccinated with ChAdOx1, 1,661,139 people vaccinated with BNT162b2, 299,311 people infected with SARS-CoV-2, and 2,290,537 people from the general population. The two vaccinated populations were similar in terms of age, sex, and clinical characteristics. The vaccinated populations were older, more often female, and had a higher prevalence of all studied comorbidities than the general population. Differences in the prevalence of comorbidities was more pronounced for younger age groups. Those infected with SARS-CoV-2 were younger than the general population. Detailed characteristics for all four cohorts are given in Table 1, and stratified by age in the Appendix. BNT162b2 vaccination started earlier than ChAdOx1 vaccination. The numbers vaccinated with the two vaccines became similar in late January 2021, and ChAdOx1 vaccines predominated in February and early March (Figure 1).

Rates of VTE were higher in men aged 50-59 vaccinated with BNT162b2 (367.5/100,000 person-years [95%CI 237.8-542.5]) than the age-sex specific background rate (211.9/100,000 person-years [200.2-224.1]) (Figure 2). Rates of VTE were also higher in women aged ≥ 80 vaccinated with ChAdOx1 (878.1/100,000 person-years [685.8-1107.6]) than the equivalent age-sex background (703.0/100,000 person-years [670.1-737.2]). Standardized SIRs for VTE were 1.07 [0.98-1.18] for ChAdOx1, 1.09 [1.00-1.20] for BNT162b2, and 8.08 [7.48-8.72] for SARS-Cov-2 (Table 2, Figure 3).

Although crude rates of DVT post-vaccination were higher than expected in some strata (Figure 2), standardization attenuated this difference, with SIRs of 0.95 [0.83-1.08] for ChAdOx1 and 1.01 [0.89-1.14] for BNT162b2 (Figure 3). DVT rates after SARS-Cov-2 infection were more than double the expected rates, with a SIR of 2.56 [2.15-3.05].

Post-vaccination rates of PE were higher than expected in some strata, such as women and men aged 50-59, women aged ≥ 80 vaccinated with ChAdOx1, and men aged 60-69 vaccinated with BNT162b2 (Figure 2). After standardization, excess PE events remained for ChAdOx1 and Bnt162n2, with SIRs of 1.23 [1.09-1.39] and 1.21 [1.07-1.36], respectively. In comparison, SARS-Cov-2 infection had a SIR of 15.31 [14.08-16.65]. Incidence rate ratios by age and sex for PE and the profiles of those with an event are summarized in the Appendix.

Few occurrences of SVT were seen, with a SIR of 1.38 [0.72-2.66] for ChAdOx1 and under 5 cases following BNT162b2 vaccination or SARS-Cov-2 infection. CVST was too rare ($n < 5$) in all three cohorts to conduct the primary analyses (see Figure 3 and below for results from sensitivity analyses).

Observed post-vaccination ATE rates were similar to expected rates (Figure 2). There were fewer ATE than expected for both vaccinated cohorts after standardization (Table 2, Figure 3). Little differences was seen between observed and expected ATE in people infected with SARS-Cov-2 (Figure 3). When analyzed separately, observed rates of myocardial infarction and ischemic stroke were also similar to expected rates following both vaccination and infection with SARS-Cov-2 (Figure 2, Figure 3).

Thrombocytopenia was more common than expected after vaccination with ChAdOx1 (SIR 1.25 [1.19-1.31]), but not after vaccination with BNT162b2 (SIR 0.99 [0.94-1.04]). Immune thrombocytopenia was more common than expected from the background population after vaccination with ChAdOx1 (SIR 2.01 [1.27-3.19]), BNT162b2 (SIR 1.74 [1.05-2.89]), and SARS-Cov-2 infection (SIR 2.83 [1.18-6.80]). Incidence rate ratios by age and sex for thrombocytopenia are summarized in the Appendix, along with the profiles of those affected.

VTE with concurrent thrombocytopenia was very rare and had similar crude rates in the background population (3.5/100,000 person-years [3.1-4.1]), after ChAdOx1 vaccination (5.9 [2.4-12.1]), and after BNT162b2 vaccination (5.1 [1.9-11.0]). There were fewer than 5 cases in the SARS-Cov-2 cohort. Standardization confirmed this finding, with SIRs of 1.09 [0.52-2.29] for ChAdOx1 and 0.86 [0.39-1.92] for BNT162b2.

ATE with thrombocytopenia was also very rare, with a rate after ChAdOx1 vaccination of 4.2/100,000 person-years [1.4-9.8] and an overall crude background rate of 1.7/100,000 person-years [1.4-2.1], equivalent to a SIR of 1.57 [0.65-3.78]. Fewer than 5 cases were identified after BNT162b2 vaccination and SARS-Cov-2 infection.

Overall crude rates of stroke with thrombocytopenia were 1.4/100,000 person-years [1.1-1.8] in the background population and 5.0 [1.8-11.0] after vaccination with ChAdOx1, equivalent to a SIR of 2.21 [0.99 to 4.91]. Again, under 5 cases were seen after BNT162b2 vaccination and SARS-Cov-2 infection, so SIR rates were not estimated. Myocardial infarction with thrombocytopenia was too rare ($n < 5$) in the vaccination and infection cohorts for analysis.

Sensitivity analyses

Results from sensitivity analyses were generally consistent with the results from the primary analyses (see Appendix). One key addition was the analysis of CVST, which was too rare for estimation in the primary analyses but could be analyzed when the requirement of a year of prior history was removed. The observed number of CVST events ($n=5$) was then higher than expected (2.2) in the ChAdOx1 cohort, resulting in a SIR of 2.32 [0.97-5.58] (Table 2, Figure 3).

All primary and sensitivity analysis results are available in an interactive web application: <https://livedataoxford.shinyapps.io/CovidVaccinationSafetyStudy/>

Discussion

Summary of results

In a cohort of 3.5 million people vaccinated against SARS-CoV-2, 74 (0.002%) more than expected suffered a VTE in the 28 days following vaccination. This higher rate was driven by more PE events after both ChAdOx1 and BNT162b2 than expected, with a 20% increase in rates of events and 93 (0.003%) excess PEs observed. The rate of PE was much larger in people infected with SARS-Cov-2, with a 15-fold relative increase and 511 (0.17%) excess PE events observed in 300,000 people.

Although observed rates of thrombocytopenia were similar to expected for people vaccinated with BNT162b2, a 25% relative increase in the rate of thrombocytopenia was seen among those vaccinated with ChAdOx1. This increase was most pronounced for younger age groups. No signal was seen for either vaccine for ATE. Finally, 3 (0.0001%) more cases than expected were seen of CVST and 3 (0.0002%) of stroke with thrombocytopenia in 1.8 million people vaccinated with ChAdOx1 in a secondary analysis.

Noticeable differences in comorbidities between the vaccinated and background cohorts suggest the potential for residual confounding, unaccounted for in our analyses.

Findings in context

Concerns over thrombosis – alone and with thrombocytopenia – have been raised from spontaneous reports data since March.^{8,9,20} Case series have been published, suggesting a new clinical entity known as vaccine-induced immune thrombotic thrombocytopenia (VITT), presenting as unusual thrombosis with raised antibodies against platelet factor 4. Only a few small studies have been conducted on this topic. A study of 280,000 vaccinees aged between 18 and 65 in Denmark and Norway assessed the 28-day incidence rates of thromboembolic events and coagulation disorders following ChAdOx1.²¹ Similar to our analyses, Pottegård et al applied a historical comparator design with indirect standardization. They found a 2-fold increased rate of VTE, an 80% increase in rates of PE, and a 20-fold increased rate of CVST. The authors also reported a 3-fold higher-than-expected rate of thrombocytopenia and a potential increase. As in our study, they observed similar rates of arterial events among those vaccinated as would be expected given rates in the general population.

More recently, a nested case-control study from Scotland found no increase in risk of VTE with either vaccine.²² The authors also reported potential increased risks of ATE and hemorrhagic events with ChAdOx1, although these were not confirmed in subsequent self-controlled case series analysis. The authors suggested that residual confounding could explain their findings. Case-control analyses based on routine health data have recently been criticized and shown to induce substantial residual bias,²³ which may explain the differences in results from those in our study and that by Pottegård et al.

Study strengths and limitations

Our study has limitations. The time period studied covered the initial phases of vaccination in the UK, when vaccines were prioritized for older, more vulnerable populations and healthcare staff.²⁴ We therefore saw a higher prevalence of conditions such as asthma and diabetes in those vaccinated than in the general population. Although we used indirect

standardization to account for differences in the four cohorts' age distributions, remaining residual confounding could explain some of our findings. Such bias could result in overestimated safety signals due to remaining imbalances in the baseline outcome risk when comparing vaccinated and background populations.

Measurement error is unavoidable in observational studies. However, any errors are likely to have been non-differential across our vaccinated and unvaccinated cohorts and should therefore not have affected our relative rate estimates. As we only used primary care data, we may have underestimated absolute risks due to a lack of hospital linkage. However, previous studies have shown that CPRD captures rare events well, even without linkage to Hospital Episode Statistics.²⁵

Although within-database comparisons are preferred,¹⁶ we had to use two slightly different primary care databases. However, one study found that these databases gave similar results.²⁶ We also used the OMOP common data model to maximize the comparability of the two databases irrespective of differences in their coding systems.

Our study also has strengths. This is the largest cohort study on the safety of COVID-19 vaccines to date. The large sample of 3.5 million vaccinees allowed us to assess very rare events that are generally not observed in clinical trials. We used a well-established source of routinely collected health data previously used for vaccine safety studies.^{27,28} Including cohorts of people infected with SARS-CoV-2 and the general population provided much needed context for interpreting our findings. Our historical comparison method ensured a timely study with high statistical power. Our protocol was pre-specified and agreed in advance with the study funder, the European Medicines Agency. Our analyses were based on data recorded before the detection of thrombosis and thrombocytopenia signals, minimizing surveillance bias.

Conclusions

In a cohort of 3.5 million people vaccinated against SARS-Cov-2, thrombosis, thrombocytopenia, and thrombosis with thrombocytopenia were very rare events. The rates of VTE and ATE were broadly similar after ChAdOx1 and BNT162b2 vaccination, although thrombocytopenia was more common among ChAdOx1 vaccinees, particularly in younger age strata. A potential safety signal for PE for both vaccines was identified. Although the occurrence of PE after vaccination was 1.2-fold above that expected in the general population, its occurrence among those contracting SARS-CoV-2 was more than 15-fold the background (expected) rate. Vaccinated people recorded more comorbidities and medicine use than the background population, suggesting potential for unresolved confounding by indication.

References

1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med*. 2020;383(27):2603-2615.
2. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *Lancet*. 2021;397(10269):99-111.
3. Hall VJ, Foulkes S, Saei A, et al. Effectiveness of BNT162b2 mRNA Vaccine Against Infection and COVID-19 Vaccine Coverage in Healthcare Workers in England, Multicentre Prospective Cohort Study (the SIREN Study). Published online February 22, 2021. doi:10.2139/ssrn.3790399
4. Vasileiou E, Simpson CR, Robertson C, et al. Effectiveness of First Dose of COVID-19 Vaccines Against Hospital Admissions in Scotland: National Prospective Cohort Study of 5.4 Million People. Published online February 19, 2021. doi:10.2139/ssrn.3789264
5. Pritchard E, Matthews PC, Stoesser N, et al. Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom. *Nat Med*. Published online June 9, 2021:1-9.
6. Vasileiou E, Simpson CR, Shi T, et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. *Lancet*. 2021;397(10285):1646-1657.
7. Cabezas C, Coma E, Mora-Fernandez N, et al. Effects of BNT162b2 mRNA vaccination on COVID-19 disease, hospitalisation and mortality in nursing homes and healthcare workers: A prospective cohort study including 28,594 nursing home residents, 26,238 nursing home staff, and 61,951 healthcare workers in Catalonia. *SSRN Electron J*. Published online April 9, 2021. doi:10.2139/ssrn.3815682
8. Schultz NH, Sørvoll IH, Michelsen AE, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. *N Engl J Med*. 2021;(NEJMoa2104882). doi:10.1056/NEJMoa2104882
9. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. *N Engl J Med*. 2021;(NEJMoa2104840). doi:10.1056/NEJMoa2104840
10. Blauenfeldt RA, Kristensen SR, Ernstsén SL, Kristensen CCH, Simonsen CZ, Hvas A-M. Thrombocytopenia with acute ischemic stroke and bleeding in a patient newly vaccinated with an adenoviral vector-based COVID-19 vaccine. *J Thromb Haemost*. 2021;(jth.15347). doi:10.1111/jth.15347
11. MHRA. Coronavirus vaccine - weekly summary of Yellow Card reporting: Updated 6 May 2021. Published May 6, 2021. Accessed May 7, 2021. <https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting>
12. Lee E-J, Cines DB, Gernsheimer T, et al. Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. *Am J Hematol*. 2021;96(5):534-537.
13. Wolf A, Dedman D, Campbell J, et al. Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum. *Int J Epidemiol*. 2019;48(6):1740-1740g.

14. Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: Clinical practice research datalink (CPRD). *Int J Epidemiol*. 2015;44(3):827-836.
15. Leite A, Thomas SL, Andrews NJ. Implementing near real-time vaccine safety surveillance using the Clinical Practice Research Datalink (CPRD). *Vaccine*. 2017;35(49 Pt B):6885-6892.
16. Li X, Ostropolets A, Makadia R, et al. Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study. *BMJ*. 2021;373:n1435.
17. Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. *J Am Med Inform Assoc*. 2012;19(1):54-60.
18. Chen MD MA R. Updated Proposed Brighton Collaboration process for developing a standard case definition for study of new clinical syndrome X, as applied to Thrombosis with Thrombocytopenia Syndrome (TTS). Published May 18, 2021. Accessed June 13, 2021. <https://brightoncollaboration.us/wp-content/uploads/2021/05/TTS-Interim-Case-Definition-v10.16.3-May-23-2021.pdf>
19. Kirkwood BR, Sterne JAC. *Essential Medical Statistics*. 2nd ed. Wiley-Blackwell; 2010.
20. Scully M, Singh D, Lown R, et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. *N Engl J Med*. 2021;384(23):2202-2211.
21. Pottegård A, Lund LC, Karlstad Ø, et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. *BMJ*. 2021;373:n1114.
22. Simpson CR, Shi T, Vasileiou E, et al. First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland. *Nat Med*. Published online June 9, 2021:1-8.
23. Schuemie MJ, Ryan PB, Man KKC, Wong ICK, Suchard MA, Hripcsak G. A plea to stop using the case-control design in retrospective database studies. *Stat Med*. 2019;38(22):4199-4208.
24. Joint Committee on Vaccination and Immunisation. Priority groups for coronavirus (COVID-19) vaccination: advice from the JCVI. Published online December 30, 2020. <https://www.gov.uk/government/publications/priority-groups-for-coronavirus-covid-19-vaccination-advice-from-the-jcvi-30-december-2020>
25. Stowe J, Andrews N, Wise L, Miller E. Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Research Database. *Am J Epidemiol*. 2009;169(3):382-388.
26. Gulliford MC, Sun X, Anjuman T, Yelland E, Murray-Thomas T. Comparison of antibiotic prescribing records in two UK primary care electronic health record systems: cohort study using CPRD GOLD and CPRD Aurum databases. *BMJ Open*. 2020;10(6):e038767.
27. Bryan P, Seabroke S, Wong J, et al. Safety of multicomponent meningococcal group B vaccine (4CMenB) in routine infant immunisation in the UK: a prospective surveillance study. *Lancet Child Adolesc Health*. 2018;2(6):395-403.

28. Grint DJ, McDonald HI, Walker JL, Amirthalingam G, Andrews N, Thomas S. Safety of inadvertent administration of live zoster vaccine to immunosuppressed individuals in a UK-based observational cohort analysis. *BMJ Open*. 2020;10(1):e034886.

Table 1. Characteristics of study participants

Characteristics of the participants in the four study cohorts used for the primary analyses. Participants were aged 30 years or older and had at least one year of prior history before index date in the database. Those in the general population had a primary care visit or contact between 2017 and 2019. People infected with SARS-CoV-2 had a confirmatory positive RT-PCR test. *Conditions of interest: autoimmune disease, antiphospholipid syndrome, thrombophilia, asthma, atrial fibrillation, malignant neoplastic disease, diabetes mellitus, obesity, or renal impairment. † Medications of interest: non-steroidal anti-inflammatory drugs, Cox2 inhibitors, systemic corticosteroids, hormonal contraceptives, tamoxifen, and sex hormones and modulators of the genital system.

	General population	Vaccinated with ChadOx1	Vaccinated with BNT162b2	Infected with SARS-CoV-2
N	2,290,537	1,868,767	1,661,139	299,311
Age (median [IQR])	54 [43 to 67]	66 [56 to 73]	67 [54 to 78]	48 [39 to 58]
Age: 30 to 39	431,801 (18.9%)	123,991 (6.6%)	135,101 (8.1%)	82,427 (27.5%)
Age: 40 to 49	459,400 (20.1%)	173,453 (9.3%)	178,503 (10.7%)	77,184 (25.8%)
Age: 50 to 59	506,515 (22.1%)	285,938 (15.3%)	279,223 (16.8%)	75,543 (25.2%)
Age: 60 to 69	403,673 (17.6%)	567,041 (30.3%)	322,252 (19.4%)	38,646 (12.9%)
Age: 70 to 79	301,179 (13.1%)	545,251 (29.2%)	372,426 (22.4%)	14,839 (5.0%)
Age: 80 or older	187,969 (8.2%)	173,093 (9.3%)	373,634 (22.5%)	10,672 (3.6%)
Sex: Male	1,094,911 (47.8%)	845,908 (45.3%)	702,863 (42.3%)	136,301 (45.5%)
Years of prior observation time (median [IQR])	13.5 [8.1 to 16.3]	19.0 [7.7 to 31.1]	19.1 [7.8 to 31.2]	12.4 [5.3 to 23.9]
Comorbidities				

Autoimmune disease	57,773 (2.5%)	72,119 (3.9%)	64,311 (3.9%)	7,136 (2.4%)
Antiphospholipid syndrome	1,046 (0.0%)	1,535 (0.1%)	1,349 (0.1%)	215 (0.1%)
Thrombophilia	2,582 (0.1%)	3,628 (0.2%)	3,192 (0.2%)	549 (0.2%)
Asthma	301,669 (13.2%)	284,126 (15.2%)	253,177 (15.2%)	45,470 (15.2%)
Atrial fibrillation	72,643 (3.2%)	100,730 (5.4%)	117,398 (7.1%)	5,993 (2.0%)
Malignant neoplastic disease	187,499 (8.2%)	257,449 (13.8%)	268,655 (16.2%)	15,663 (5.2%)
Diabetes mellitus	197,619 (8.6%)	306,944 (16.4%)	276,194 (16.6%)	28,488 (9.5%)
Obesity	94,054 (4.1%)	120,052 (6.4%)	98,900 (6.0%)	16,791 (5.6%)
Heart disease	251,708 (11.0%)	334,469 (17.9%)	349,669 (21.0%)	24,511 (8.2%)
Hypertensive disorder	533,750 (23.3%)	677,743 (36.3%)	643,345 (38.7%)	53,921 (18.0%)
Renal impairment	161,596 (7.1%)	207,751 (11.1%)	234,386 (14.1%)	14,150 (4.7%)
Chronic Obstructive Pulmonary Disease	77,205 (3.4%)	107,636 (5.8%)	95,654 (5.8%)	5,384 (1.8%)
Dementia	29,376 (1.3%)	38,589 (2.1%)	34,829 (2.1%)	4,886 (1.6%)
<i>Medication use (183 days prior to four days prior)</i>				
Non-steroidal anti- inflammatory drugs	618,552 (27.0%)	264,090 (14.1%)	242,309 (14.6%)	33,299 (11.1%)
Cox2 inhibitors	6,115 (0.3%)	1,931 (0.1%)	1,581 (0.1%)	258 (0.1%)
Systemic corticosteroids	263,488 (11.5%)	119,766 (6.4%)	105,977 (6.4%)	14,168 (4.7%)

Antithrombotic and anticoagulant therapies	102,605 (4.5%)	61,322 (3.3%)	65,237 (3.9%)	3,885 (1.3%)
Lipid modifying agents	130,264 (5.7%)	110,329 (5.9%)	102,835 (6.2%)	8,224 (2.7%)
Antineoplastic and immunomodulating agents	57,403 (2.5%)	20,445 (1.1%)	20,541 (1.2%)	3,822 (1.3%)
Hormonal contraceptives for systemic use	76,796 (3.4%)	18,566 (1.0%)	20,491 (1.2%)	7,205 (2.4%)
Tamoxifen	1,957 (0.1%)	814 (0.0%)	799 (0.0%)	87 (0.0%)
Sex hormones and modulators of the genital system	110,583 (4.8%)	44,612 (2.4%)	44,563 (2.7%)	10,283 (3.4%)
Summary count of conditions and medications of interest				
One or more condition of interest*	579,628 (25.3%)	778,559 (41.7%)	751,224 (45.2%)	68,879 (23.0%)
One or more medication of interest [†]	758,348 (33.1%)	345,875 (18.5%)	318,704 (19.2%)	47,239 (15.8%)
One or more condition/medication of interest* [†]	1,058,141 (46.2%)	949,193 (50.8%)	897,757 (54.0%)	99,727 (33.3%)

Table 2. Observed versus expected events among people vaccinated against SARS-CoV-2 or with a positive PCR test for SARS-CoV-2

For each event of interest, the number of people contributing to the analysis from the target population, their person-years contributed, and the number of observed events are given. Expected events are estimated using indirect standardization to the general population. Standardized incidence ratios (SIRs) with 95% confidence intervals (CIs) were estimated. Events with fewer than 5 occurrences were omitted for privacy reasons: cerebral venous sinus thrombosis and splanchnic vein thrombosis (BNT162b2 and SARS-CoV-2), venous thromboembolism with thrombocytopenia (SARS-CoV-2), and myocardial infarction or ischemic stroke with thrombocytopenia (BNT162b2 and SARS-CoV-2).

*Cerebral venous sinus thrombosis is reported without the requirement for a year of prior history as fewer than 5 events were seen when this restriction was imposed.

	N	Person-years	Observed events	Expected events	Standardised event difference proportion %	SIR (95% CI)
Thrombosis						
<i>Cerebral venous sinus thrombosis (CVST)*</i>						
Vaccinated with ChAdOx1	1,956,136	124,569	5	2.2	0.0001%	2.32 (0.97 to 5.58)
<i>Deep vein thrombosis (DVT)</i>						
Vaccinated with ChAdOx1	1,863,668	118,809	226	237.9	-0.0006%	0.95 (0.83 to 1.08)
Vaccinated with BNT162b2	1,656,875	118,344	254	251.3	0.0002%	1.01 (0.89 to 1.14)

SARS-CoV-2 PCR positive test	298,776	40,528	125	48.8	0.0255%	2.56 (2.15 to 3.05)
<i>Pulmonary embolism (PE)</i>						
Vaccinated with ChAdOx1	1,863,403	118,787	259	210.4	0.0026%	1.23 (1.09 to 1.39)
Vaccinated with BNT162b2	1,656,755	118,336	261	216.4	0.0027%	1.21 (1.07 to 1.36)
SARS-CoV-2 PCR positive test	298,786	40,491	547	35.7	0.1711%	15.31 (14.08 to 16.65)
<i>Splanchnic Vein Thrombosis (SVT)</i>						
Vaccinated with ChAdOx1	1,868,536	119,132	9	6.5	0.0001%	1.38 (0.72 to 2.66)
<i>Venous thromboembolism (VTE)</i>						
Vaccinated with ChAdOx1	1,858,837	118,483	461	429.2	0.0017%	1.07 (0.98 to 1.18)
Vaccinated with BNT162b2	1,652,892	118,054	491	448.6	0.0026%	1.09 (1.00 to 1.20)
SARS-CoV-2 PCR positive test	298,397	40,429	646	80	0.1897%	8.08 (7.48 to 8.72)
<i>Myocardial infarction</i>						

Vaccinated with ChAdOx1	1,861,365	118,643	347	411.3	-0.0035%	0.84 (0.76 to 0.94)
Vaccinated with BNT162b2	1,654,037	118,145	356	433.4	-0.0047%	0.82 (0.74 to 0.91)
SARS-CoV-2 PCR positive test	298,632	40,509	79	65.7	0.0045%	1.20 (0.96 to 1.50)
<i>Ischemic stroke</i>						
Vaccinated with ChAdOx1	1,867,000	119,025	72	95.8	-0.0013%	0.75 (0.60 to 0.95)
Vaccinated with BNT162b2	1,659,635	118,542	120	108.5	0.0007%	1.11 (0.92 to 1.32)
SARS-CoV-2 PCR positive test	299,100	40,582	13	12.3	0.0002%	1.05 (0.61 to 1.81)
<i>ATE (Myocardial infarction or ischemic stroke)</i>						
Vaccinated with ChAdOx1	1,858,974	118,481	406	503.7	-0.0053%	0.81 (0.73 to 0.89)
Vaccinated with BNT162b2	1,651,903	117,990	458	538.3	-0.0049%	0.85 (0.78 to 0.93)
SARS-CoV-2 PCR positive test	298,464	40,485	88	77.6	0.0035%	1.13 (0.92 to 1.40)
<i>Stroke</i>						

Vaccinated with ChAdOx1	1,861,358	118,629	413	405	0.0004%	1.02 (0.93 to 1.12)
Vaccinated with BNT162b2	1,654,569	118,167	457	454	0.0002%	1.01 (0.92 to 1.10)
SARS-CoV-2 PCR positive test	298,709	40,525	65	54.5	0.0035%	1.19 (0.93 to 1.52)
Thrombocytopenia						
<i>Immune thrombocytopenia</i>						
Vaccinated with ChAdOx1	1,868,376	119,120	18	8.9	0.0005%	2.01 (1.27 to 3.19)
Vaccinated with BNT162b2	1,660,786	118,628	15	8.6	0.0004%	1.74 (1.05 to 2.89)
SARS-CoV-2 PCR positive test	299,175	40,593	5	1.8	0.0011%	2.83 (1.18 to 6.80)
Thrombocytopenia						
Vaccinated with ChAdOx1	1,840,495	117,121	1,707	1,368.00	0.0184%	1.25 (1.19 to 1.31)
Vaccinated with BNT162b2	1,632,328	116,491	1,462	1,477.10	-0.0009%	0.99 (0.94 to 1.04)
SARS-CoV-2 PCR positive test	296,999	40,289	254	248.6	0.0018%	1.02 (0.90 to 1.16)

<i>VTE with thrombocytopenia</i>						
Vaccinated with ChAdOx1	1,868,547	119,132	7	6.4	0.0000%	1.09 (0.52 to 2.29)
Vaccinated with BNT162b2	1,660,964	118,641	6	6.9	-0.0001%	0.86 (0.39 to 1.92)
<i>ATE with thrombocytopenia</i>						
Vaccinated with ChAdOx1	1,868,580	119,135	5	3.2	0.0001%	1.57 (0.65 to 3.78)
<i>Stroke with thrombocytopenia</i>						
Vaccinated with ChAdOx1	1,868,605	119,136	6	2.7	0.0002%	2.21 (0.99 to 4.91)

Figure 1. Distribution of age profiles and date of cohort entry among people vaccinated against SARS-CoV-2

Figure 2. Background and post-vaccine rates of thromboembolic events and thrombocytopenia by age and sex
 Events with less than 5 occurrences have been omitted for privacy reasons.

Figure 3. Expected versus observed events among those vaccinated against SARS-CoV-2 and those with a SARS-CoV-2 infection

Expected events for each of the study cohorts based on indirect standardization using rates from the general population between 2017 and 2019 are compared with the number of observed events seen in each cohort on the panels on the left. Corresponding standardized incidence ratios (SIRs) with 95% confidence intervals (95% CI) are shown in the panels on the right.

■ SARS-CoV-2 PCR positive test ■ Vaccinated with BNT162b2 ■ Vaccinated with ChAdOx1

Funding

This study was funded by the European Medicines Agency in the form of a competitive tender (Lot ROC No EMA/2017/09/PE). This document expresses the opinion of the authors of the paper, and may not be understood or quoted as being made on behalf of or reflecting the position of the European Medicines Agency or one of its committees or working parties. ER was supported by Instituto de Salud Carlos III (grant number CM20/00174). DPA is funded through a National Institute for Health Research (NIHR) Senior Research Fellowship (Grant number SRF-2018-11-ST2-004).

Ethical approvals

The protocol for this research was approved by the Independent Scientific Advisory Committee (ISAC) for MHRA Database Research (protocol number 20_000211).

Acknowledgements

This study was funded by the European Medicines Agency in the form of a competitive tender (Lot ROC No EMA/2017/09/PE). We acknowledge Prof Johan Van der Lei for the overall management of this research grant.

Declarations of interest

DPA's research group has received research grants from the European Medicines Agency, from the Innovative Medicines Initiative, from Amgen, Chiesi, and from UCB Biopharma; and consultancy or speaker fees from Astellas, Amgen and UCB Biopharma.

Appendix

Patient characteristics by age group

Characteristics of study participants aged: 30 to 44

The characteristics of the study cohorts used for the primary analyses, all with the requirement to be aged 30 years or older and with a year of prior history observed in the database. Those in the general population had a primary care visit/ contact between 2017 and 2019 while persons infected with SARS-CoV-2 had a confirmatory positive RT-PCR test. *Conditions of interest: autoimmune disease, antiphospholipid syndrome, thrombophilia, asthma, atrial fibrillation, malignant neoplastic disease, diabetes mellitus, obesity, or renal impairment. †Medications of interest included non-steroidal anti-inflammatory drugs, Cox2 inhibitors, systemic corticosteroids, hormonal contraceptives, tamoxifen, and sex hormones and modulators of the genital system

	General population	Vaccinated with ChAdOx1	Vaccinated with BNT162b2	SARS-CoV-2 PCR positive test
N	644,372	202,865	217,319	121,692
Age	37 [33 to 41]	38 [34 to 41]	38 [34 to 41]	37 [33 to 41]
Age: 30 to 39	431,801 (67.0%)	123,991 (61.1%)	135,101 (62.2%)	82,427 (67.7%)
Age: 40 to 49	212,571 (33.0%)	78,874 (38.9%)	82,218 (37.8%)	39,265 (32.3%)
Sex: Male	306,045 (47.5%)	74,116 (36.5%)	70,735 (32.5%)	53,806 (44.2%)
Years of prior observation time	10.4 [4.8 to 14.9]	8.3 [4.1 to 15.9]	7.7 [3.8 to 14.9]	7.9 [3.8 to 15.7]
Comorbidities				
Autoimmune disease	8,875 (1.4%)	5,779 (2.8%)	5,283 (2.4%)	1,847 (1.5%)
Antiphospholipid syndrome	259 (0.0%)	273 (0.1%)	251 (0.1%)	76 (0.1%)
Thrombophilia	851 (0.1%)	660 (0.3%)	654 (0.3%)	227 (0.2%)
Asthma	102,513 (15.9%)	47,467 (23.4%)	46,382 (21.3%)	20,043 (16.5%)
Atrial fibrillation	927 (0.1%)	879 (0.4%)	863 (0.4%)	192 (0.2%)
Malignant neoplastic disease	7,288 (1.1%)	5,844 (2.9%)	5,492 (2.5%)	1,356 (1.1%)
Diabetes mellitus	17,185 (2.7%)	27,531 (13.6%)	19,860 (9.1%)	5,576 (4.6%)
Obesity	18,089 (2.8%)	13,635 (6.7%)	11,684 (5.4%)	4,815 (4.0%)
Heart disease	11,653 (1.8%)	10,509 (5.2%)	9,827 (4.5%)	2,886 (2.4%)
Hypertensive disorder	20,630 (3.2%)	13,490 (6.6%)	12,430 (5.7%)	4,910 (4.0%)

Renal impairment	4,449 (0.7%)	4,107 (2.0%)	3,695 (1.7%)	1,149 (0.9%)
COPD	929 (0.1%)	911 (0.4%)	613 (0.3%)	96 (0.1%)
Dementia	772 (0.1%)	738 (0.4%)	638 (0.3%)	206 (0.2%)
Medication use (183 days prior to four days prior)				
Non-steroidal anti-inflammatory drugs	107,115 (16.6%)	20,685 (10.2%)	18,571 (8.5%)	9,204 (7.6%)
Cox2 inhibitors	933 (0.1%)	183 (0.1%)	147 (0.1%)	54 (0.0%)
Systemic corticosteroids	44,535 (6.9%)	10,629 (5.2%)	9,351 (4.3%)	4,406 (3.6%)
Antithrombotic and anticoagulant therapies	4,599 (0.7%)	1,031 (0.5%)	789 (0.4%)	269 (0.2%)
Lipid modifying agents	4,098 (0.6%)	1,861 (0.9%)	1,543 (0.7%)	490 (0.4%)
Antineoplastic and immunomodulating agents	29,367 (4.6%)	5,402 (2.7%)	6,002 (2.8%)	2,591 (2.1%)
Hormonal contraceptives for systemic use	50,360 (7.8%)	9,897 (4.9%)	11,305 (5.2%)	5,000 (4.1%)
Tamoxifen	190 (0.0%)	47 (0.0%)	44 (0.0%)	14 (0.0%)
Sex hormones and modulators of the genital system	52,721 (8.2%)	10,572 (5.2%)	11,987 (5.5%)	5,268 (4.3%)
One or more condition of interest*	52,792 (8.2%)	50,913 (25.1%)	41,923 (19.3%)	13,637 (11.2%)
One or more medication of interest [†]	158,520 (24.6%)	33,547 (16.5%)	32,307 (14.9%)	15,456 (12.7%)
One or more condition/ medication of interest* [†]	191,069 (29.7%)	73,997 (36.5%)	65,853 (30.3%)	26,342 (21.6%)

Characteristics of study participants: aged 45 to 64

The characteristics of the study cohorts used for the primary analyses, all with the requirement to be aged 30 years or older and with a year of prior history observed in the database. Those in the general population had a primary care visit/ contact between 2017 and 2019 while persons infected with SARS-CoV-2 had a confirmatory positive RT-PCR test. *Conditions of interest: autoimmune disease, antiphospholipid syndrome, thrombophilia, asthma, atrial fibrillation, malignant neoplastic disease, diabetes mellitus, obesity, or renal impairment. †Medications of interest included non-steroidal anti-inflammatory drugs, Cox2 inhibitors, systemic corticosteroids, hormonal contraceptives, tamoxifen, and sex hormones and modulators of the genital system

	General population	Vaccinated with ChAdOx1	Vaccinated with BNT162b2	SARS-CoV-2 PCR positive test
N	963,696	624,698	534,049	138,195
Age	54 [49 to 59]	57 [52 to 62]	56 [51 to 60]	53 [49 to 58]
Age: 40 to 49	246,829 (25.6%)	94,579 (15.1%)	96,285 (18.0%)	37,919 (27.4%)
Age: 50 to 59	506,515 (52.6%)	285,938 (45.8%)	279,223 (52.3%)	75,543 (54.7%)
Age: 60 to 69	210,352 (21.8%)	244,181 (39.1%)	158,541 (29.7%)	24,733 (17.9%)
Age: 70 to 79	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Age: 80 or older	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Sex: Male	476,832 (49.5%)	287,869 (46.1%)	215,350 (40.3%)	64,807 (46.9%)
Years of prior observation time	13.8 [9.4 to 16.5]	16.9 [7.5 to 27.0]	16.6 [7.6 to 26.4]	16.0 [7.4 to 25.3]
Comorbidities				
Autoimmune disease	22,807 (2.4%)	24,114 (3.9%)	20,452 (3.8%)	3,497 (2.5%)
Antiphospholipid syndrome	553 (0.1%)	785 (0.1%)	670 (0.1%)	125 (0.1%)
Thrombophilia	1,247 (0.1%)	1,721 (0.3%)	1,511 (0.3%)	284 (0.2%)
Asthma	120,450 (12.5%)	107,823 (17.3%)	94,363 (17.7%)	19,830 (14.3%)
Atrial fibrillation	10,190 (1.1%)	12,981 (2.1%)	12,425 (2.3%)	1,594 (1.2%)
Malignant neoplastic disease	49,036 (5.1%)	53,877 (8.6%)	47,018 (8.8%)	6,929 (5.0%)
Diabetes mellitus	70,192 (7.3%)	102,585 (16.4%)	90,441 (16.9%)	14,163 (10.2%)
Obesity	43,294 (4.5%)	48,229 (7.7%)	40,960 (7.7%)	9,226 (6.7%)
Heart disease	60,885 (6.3%)	73,169 (11.7%)	66,530 (12.5%)	9,890 (7.2%)
Hypertensive disorder	173,364 (18.0%)	164,162 (26.3%)	137,388 (25.7%)	28,262 (20.5%)

Renal impairment	26,427 (2.7%)	32,833 (5.3%)	28,361 (5.3%)	4,445 (3.2%)
COPD	21,130 (2.2%)	27,484 (4.4%)	20,039 (3.8%)	2,056 (1.5%)
Dementia	1,914 (0.2%)	2,642 (0.4%)	1,983 (0.4%)	370 (0.3%)
Medication use (183 days prior to four days prior)				
Non-steroidal anti-inflammatory drugs	234,513 (24.3%)	79,342 (12.7%)	65,776 (12.3%)	15,556 (11.3%)
Cox2 inhibitors	3,024 (0.3%)	793 (0.1%)	609 (0.1%)	161 (0.1%)
Systemic corticosteroids	97,185 (10.1%)	36,413 (5.8%)	29,039 (5.4%)	6,364 (4.6%)
Antithrombotic and anticoagulant therapies	25,233 (2.6%)	12,124 (1.9%)	10,842 (2.0%)	1,489 (1.1%)
Lipid modifying agents	47,616 (4.9%)	28,586 (4.6%)	24,220 (4.5%)	4,436 (3.2%)
Antineoplastic and immunomodulating agents	14,370 (1.5%)	5,635 (0.9%)	4,958 (0.9%)	874 (0.6%)
Hormonal contraceptives for systemic use	25,338 (2.6%)	7,644 (1.2%)	8,444 (1.6%)	2,172 (1.6%)
Tamoxifen	1,095 (0.1%)	449 (0.1%)	438 (0.1%)	61 (0.0%)
Sex hormones and modulators of the genital system	43,992 (4.6%)	19,408 (3.1%)	20,440 (3.8%)	4,542 (3.3%)
One or more condition of interest*	187,548 (19.5%)	221,112 (35.4%)	195,178 (36.5%)	33,104 (24.0%)
One or more medication of interest†	288,508 (29.9%)	108,882 (17.4%)	93,553 (17.5%)	21,648 (15.7%)
One or more condition/medication of interest*†	395,455 (41.0%)	283,344 (45.4%)	248,153 (46.5%)	47,564 (34.4%)

Characteristics of study participants: age 65 or older

The characteristics of the study cohorts used for the primary analyses, all with the requirement to be aged 30 years or older and with a year of prior history observed in the database. Those in the general population had a primary care visit/ contact between 2017 and 2019 while persons infected with SARS-CoV-2 had a confirmatory positive RT-PCR test. *Conditions of interest: autoimmune disease, antiphospholipid syndrome, thrombophilia, asthma, atrial fibrillation, malignant neoplastic disease, diabetes mellitus, obesity, or renal impairment. †Medications of interest included non-steroidal anti-inflammatory drugs, Cox2 inhibitors, systemic corticosteroids, hormonal contraceptives, tamoxifen, and sex hormones and modulators of the genital system

	General population	Vaccinated with ChAdOx1	Vaccinated with BNT162b2	SARS-CoV-2 PCR positive test
N	682,469	1,041,204	909,771	39,424
Age	74 [69 to 80]	73 [69 to 77]	77 [71 to 83]	73 [68 to 80]
Age: 60 to 69	193,321 (28.3%)	322,860 (31.0%)	163,711 (18.0%)	13,913 (35.3%)
Age: 70 to 79	301,179 (44.1%)	545,251 (52.4%)	372,426 (40.9%)	14,839 (37.6%)
Age: 80 or older	187,969 (27.5%)	173,093 (16.6%)	373,634 (41.1%)	10,672 (27.1%)
Sex: Male	312,034 (45.7%)	483,923 (46.5%)	416,778 (45.8%)	17,688 (44.9%)
Years of prior observation time	14.3 [12.2 to 17.3]	23.6 [10.1 to 34.6]	24.9 [11.4 to 35.6]	20.6 [6.8 to 32.8]
Comorbidities				
Autoimmune disease	26,091 (3.8%)	42,226 (4.1%)	38,576 (4.2%)	1,792 (4.5%)
Antiphospholipid syndrome	234 (0.0%)	477 (0.0%)	428 (0.0%)	14 (0.0%)
Thrombophilia	484 (0.1%)	1,247 (0.1%)	1,027 (0.1%)	38 (0.1%)
Asthma	78,706 (11.5%)	128,836 (12.4%)	112,432 (12.4%)	5,597 (14.2%)
Atrial fibrillation	61,526 (9.0%)	86,870 (8.3%)	104,110 (11.4%)	4,207 (10.7%)
Malignant neoplastic disease	131,175 (19.2%)	197,728 (19.0%)	216,145 (23.8%)	7,378 (18.7%)
Diabetes mellitus	110,242 (16.2%)	176,828 (17.0%)	165,893 (18.2%)	8,749 (22.2%)
Obesity	32,671 (4.8%)	58,188 (5.6%)	46,256 (5.1%)	2,750 (7.0%)
Heart disease	179,170 (26.3%)	250,791 (24.1%)	273,312 (30.0%)	11,735 (29.8%)
Hypertensive disorder	339,756 (49.8%)	500,091 (48.0%)	493,527 (54.2%)	20,749 (52.6%)
Renal impairment	130,720 (19.2%)	170,811 (16.4%)	202,330 (22.2%)	8,556 (21.7%)
COPD	55,146 (8.1%)	79,241 (7.6%)	75,002 (8.2%)	3,232 (8.2%)

Dementia	26,690 (3.9%)	35,209 (3.4%)	32,208 (3.5%)	4,310 (10.9%)
Medication use (183 days prior to four days prior)				
Non-steroidal anti-inflammatory drugs	276,924 (40.6%)	164,063 (15.8%)	157,962 (17.4%)	8,539 (21.7%)
Cox2 inhibitors	2,158 (0.3%)	955 (0.1%)	825 (0.1%)	43 (0.1%)
Systemic corticosteroids	121,768 (17.8%)	72,724 (7.0%)	67,587 (7.4%)	3,398 (8.6%)
Antithrombotic and anticoagulant therapies	72,773 (10.7%)	48,167 (4.6%)	53,606 (5.9%)	2,127 (5.4%)
Lipid modifying agents	78,550 (11.5%)	79,882 (7.7%)	77,072 (8.5%)	3,298 (8.4%)
Antineoplastic and immunomodulating agents	13,666 (2.0%)	9,408 (0.9%)	9,581 (1.1%)	357 (0.9%)
Hormonal contraceptives for systemic use	1,098 (0.2%)	1,025 (0.1%)	742 (0.1%)	33 (0.1%)
Tamoxifen	672 (0.1%)	318 (0.0%)	317 (0.0%)	12 (0.0%)
Sex hormones and modulators of the genital system	13,870 (2.0%)	14,632 (1.4%)	12,136 (1.3%)	473 (1.2%)
One or more condition of interest*	339,288 (49.7%)	506,534 (48.6%)	514,123 (56.5%)	22,138 (56.2%)
One or more medication of interest [†]	311,320 (45.6%)	203,446 (19.5%)	192,844 (21.2%)	10,135 (25.7%)
One or more condition/ medication of interest* [†]	471,617 (69.1%)	591,852 (56.8%)	583,751 (64.2%)	25,821 (65.5%)

Results for all study outcomes

For each event of interest the number of persons contributing to the analysis from the target population, their person-years contributed, and the number of events observed for them are given. Their expected events are estimated using indirect standardisation to the general population, with expected events giving the number of events we would have expected to have seen if their outcome experience was the same as that of the general population. Standardised incidence ratios (SIRs) with 95% confidence intervals (CIs) were estimated. Events with less than 5 occurrences have been omitted for privacy reasons. *Cerebral venous sinus thrombosis is reported without the requirement for a year of prior history as less than 5 events were seen when this restriction was imposed.

Event	Cohort	N	Person-years	Observed events	Expected events	SIR (95% CI)
Cerebral venous sinus thrombosis*	Vaccinated with ChAdOx1	1,956,136	124,569	5	2.2	2.32 (0.97 to 5.58)
Deep vein thrombosis - broad	Vaccinated with ChAdOx1	1,862,896	118,757	275	255.1	1.08 (0.96 to 1.21)
Deep vein thrombosis - broad	Vaccinated with BNT162b2	1,656,235	118,297	296	268.1	1.10 (0.99 to 1.24)
Deep vein thrombosis - broad	SARS-CoV-2 PCR positive test	298,707	40,517	143	53.2	2.69 (2.28 to 3.17)
Deep vein thrombosis - narrow	Vaccinated with ChAdOx1	1,863,668	118,809	226	237.9	0.95 (0.83 to 1.08)
Deep vein thrombosis - narrow	Vaccinated with BNT162b2	1,656,875	118,344	254	251.3	1.01 (0.89 to 1.14)
Deep vein thrombosis - narrow	SARS-CoV-2 PCR positive test	298,776	40,528	125	48.8	2.56 (2.15 to 3.05)
Deep vein thrombosis broad with thrombocytopenia 10 days pre to 10 days post	Vaccinated with ChAdOx1	1,868,584	119,135	6	4.1	1.45 (0.65 to 3.23)
Deep vein thrombosis broad with thrombocytopenia 42 days pre to 14 days post	Vaccinated with ChAdOx1	1,868,547	119,132	9	7.4	1.22 (0.64 to 2.35)
Deep vein thrombosis narrow with thrombocytopenia 42 days pre to 14 days post	Vaccinated with ChAdOx1	1,868,554	119,133	7	7	1.00 (0.48 to 2.11)

Hemorrhagic stroke	Vaccinated with ChAdOx1	1,867,822	119,084	45	43.1	1.04 (0.78 to 1.40)
Hemorrhagic stroke	Vaccinated with BNT162b2	1,660,431	118,603	38	46.8	0.81 (0.59 to 1.12)
Hemorrhagic stroke	SARS-CoV-2 PCR positive test	299,127	40,584	11	8.2	1.34 (0.74 to 2.42)
Immune thrombocytopenia	Vaccinated with ChAdOx1	1,868,376	119,120	18	8.9	2.01 (1.27 to 3.19)
Immune thrombocytopenia	Vaccinated with BNT162b2	1,660,786	118,628	15	8.6	1.74 (1.05 to 2.89)
Immune thrombocytopenia	SARS-CoV-2 PCR positive test	299,175	40,593	5	1.8	2.83 (1.18 to 6.80)
Intestinal infarction	Vaccinated with ChAdOx1	1,868,365	119,120	13	15.1	0.86 (0.50 to 1.48)
Intestinal infarction	Vaccinated with BNT162b2	1,660,825	118,631	17	15.5	1.10 (0.68 to 1.77)
Ischemic stroke	Vaccinated with ChAdOx1	1,867,000	119,025	72	95.8	0.75 (0.60 to 0.95)
Ischemic stroke	Vaccinated with BNT162b2	1,659,635	118,542	120	108.5	1.11 (0.92 to 1.32)
Ischemic stroke	SARS-CoV-2 PCR positive test	299,100	40,582	13	12.3	1.05 (0.61 to 1.81)
Myocardial infarction	Vaccinated with ChAdOx1	1,861,365	118,643	347	411.3	0.84 (0.76 to 0.94)
Myocardial infarction	Vaccinated with BNT162b2	1,654,037	118,145	356	433.4	0.82 (0.74 to 0.91)
Myocardial infarction	SARS-CoV-2 PCR positive test	298,632	40,509	79	65.7	1.20 (0.96 to 1.50)
Myocardial infarction or ischemic stroke	Vaccinated with ChAdOx1	1,858,974	118,481	406	503.7	0.81 (0.73 to 0.89)
Myocardial infarction or ischemic stroke	Vaccinated with BNT162b2	1,651,903	117,990	458	538.3	0.85 (0.78 to 0.93)

Myocardial infarction or ischemic stroke	SARS-CoV-2 PCR positive test	298,464	40,485	88	77.6	1.13 (0.92 to 1.40)
Myocardial infarction or ischemic stroke with thrombocytopenia 10 days pre to 10 days post	Vaccinated with ChAdOx1	1,868,580	119,135	5	3.2	1.57 (0.65 to 3.78)
Myocardial infarction or ischemic stroke with thrombocytopenia 42 days pre to 14 days post	Vaccinated with ChAdOx1	1,868,524	119,131	10	6.5	1.53 (0.82 to 2.84)
Myocardial infarction or ischemic stroke with thrombocytopenia 42 days pre to 14 days post	Vaccinated with BNT162b2	1,660,931	118,639	6	8.3	0.72 (0.32 to 1.61)
Platelet disorder	Vaccinated with ChAdOx1	1,865,323	118,905	198	86.6	2.29 (1.99 to 2.63)
Platelet disorder	Vaccinated with BNT162b2	1,657,943	118,416	174	88.1	1.98 (1.70 to 2.29)
Platelet disorder	SARS-CoV-2 PCR positive test	298,922	40,552	57	15.9	3.60 (2.77 to 4.66)
Portal vein thrombosis	Vaccinated with ChAdOx1	1,868,539	119,133	8	5.4	1.48 (0.74 to 2.95)
Pulmonary embolism	Vaccinated with ChAdOx1	1,863,403	118,787	259	210.4	1.23 (1.09 to 1.39)
Pulmonary embolism	Vaccinated with BNT162b2	1,656,755	118,336	261	216.4	1.21 (1.07 to 1.36)
Pulmonary embolism	SARS-CoV-2 PCR positive test	298,786	40,491	547	35.7	15.31 (14.08 to 16.65)
Pulmonary embolism with thrombocytopenia 42 days pre to 14 days post	Vaccinated with ChAdOx1	1,868,576	119,134	6	5.5	1.09 (0.49 to 2.43)
Pulmonary embolism with thrombocytopenia 42 days pre to 14 days post	Vaccinated with BNT162b2	1,660,999	118,644	7	5.9	1.18 (0.56 to 2.48)
Pulmonary embolism with thrombocytopenia 42 days pre to 14 days post	SARS-CoV-2 PCR positive test	299,208	40,596	6	0.7	8.25 (3.71 to 18.37)
Splanchnic Vein Thrombosis	Vaccinated with ChAdOx1	1,868,536	119,132	9	6.5	1.38 (0.72 to 2.66)
Stroke	Vaccinated with ChAdOx1	1,861,358	118,629	413	405	1.02 (0.93 to 1.12)

Stroke	Vaccinated with BNT162b2	1,654,569	118,167	457	454	1.01 (0.92 to 1.10)
Stroke	SARS-CoV-2 PCR positive test	298,709	40,525	65	54.5	1.19 (0.93 to 1.52)
Stroke with thrombocytopenia 10 days pre to 10 days post	Vaccinated with ChAdOx1	1,868,605	119,136	6	2.7	2.21 (0.99 to 4.91)
Stroke with thrombocytopenia 42 days pre to 14 days post	Vaccinated with ChAdOx1	1,868,573	119,134	6	5.8	1.03 (0.46 to 2.29)
Stroke with thrombocytopenia 42 days pre to 14 days post	Vaccinated with BNT162b2	1,660,982	118,643	8	6.9	1.16 (0.58 to 2.32)
Thrombocytopenia	Vaccinated with ChAdOx1	1,840,495	117,121	1,707	1,368.00	1.25 (1.19 to 1.31)
Thrombocytopenia	Vaccinated with BNT162b2	1,632,328	116,491	1,462	1,477.10	0.99 (0.94 to 1.04)
Thrombocytopenia	SARS-CoV-2 PCR positive test	296,999	40,289	254	248.6	1.02 (0.90 to 1.16)
Thrombocytopenic purpura	Vaccinated with ChAdOx1	1,868,562	119,134	12	8	1.49 (0.85 to 2.63)
Thrombocytopenic purpura	Vaccinated with BNT162b2	1,660,955	118,641	5	7.9	0.64 (0.26 to 1.53)
Venous thromboembolism - broad	Vaccinated with ChAdOx1	1,858,064	118,431	508	445.4	1.14 (1.05 to 1.24)
Venous thromboembolism - broad	Vaccinated with BNT162b2	1,652,244	118,007	532	464.6	1.15 (1.05 to 1.25)
Venous thromboembolism - broad	SARS-CoV-2 PCR positive test	298,329	40,418	664	84.2	7.89 (7.31 to 8.51)
Venous thromboembolism - narrow	Vaccinated with ChAdOx1	1,858,837	118,483	461	429.2	1.07 (0.98 to 1.18)
Venous thromboembolism - narrow	Vaccinated with BNT162b2	1,652,892	118,054	491	448.6	1.09 (1.00 to 1.20)
Venous thromboembolism - narrow	SARS-CoV-2 PCR positive test	298,397	40,429	646	80	8.08 (7.48 to 8.72)

Venous thromboembolism broad with thrombocytopenia 10 days pre to 10 days post	Vaccinated with ChAdOx1	1,868,543	119,132	9	6.7	1.35 (0.70 to 2.60)
Venous thromboembolism broad with thrombocytopenia 10 days pre to 10 days post	Vaccinated with BNT162b2	1,660,959	118,641	6	7.1	0.84 (0.38 to 1.87)
Venous thromboembolism broad with thrombocytopenia 42 days pre to 14 days post	Vaccinated with ChAdOx1	1,868,467	119,126	14	12.3	1.13 (0.67 to 1.92)
Venous thromboembolism broad with thrombocytopenia 42 days pre to 14 days post	Vaccinated with BNT162b2	1,660,896	118,636	10	13.3	0.75 (0.41 to 1.40)
Venous thromboembolism broad with thrombocytopenia 42 days pre to 14 days post	SARS-CoV-2 PCR positive test	299,199	40,595	6	1.7	3.56 (1.60 to 7.93)
Venous thromboembolism narrow with thrombocytopenia 10 days pre to 10 days post	Vaccinated with ChAdOx1	1,868,547	119,132	7	6.4	1.09 (0.52 to 2.29)
Venous thromboembolism narrow with thrombocytopenia 10 days pre to 10 days post	Vaccinated with BNT162b2	1,660,964	118,641	6	6.9	0.86 (0.39 to 1.92)
Venous thromboembolism narrow with thrombocytopenia 42 days pre to 14 days post	Vaccinated with ChAdOx1	1,868,472	119,127	12	12	1.00 (0.57 to 1.76)
Venous thromboembolism narrow with thrombocytopenia 42 days pre to 14 days post	Vaccinated with BNT162b2	1,660,903	118,637	10	13	0.77 (0.42 to 1.44)
Venous thromboembolism narrow with thrombocytopenia 42 days pre to 14 days post	SARS-CoV-2 PCR positive test	299,199	40,595	6	1.6	3.72 (1.67 to 8.29)

Results for vaccinated stratified by calendar month

For each event of interest the number of persons contributing to the analysis from the target population, their person-years contributed, and the number of events observed for them are given. Their expected events are estimated using indirect standardisation to the general population, with expected events giving the number of events we would have expected to have seen if their outcome experience was the same as that of the general population. Standardised incidence ratios (SIRs) with 95% confidence intervals (CIs) were estimated. Events with less than 5 occurrences have been omitted for privacy reasons.

Event	Cohort	Month	N	Person-years	Observed events	Expected events	SIR (95% CI)
Deep vein thrombosis - broad	Vaccinated with ChAdOx1	January	500,670	38,273	120	100.4	1.20 (1.00 to 1.43)
Deep vein thrombosis - broad	Vaccinated with ChAdOx1	February	1,057,526	72,316	144	143	1.01 (0.86 to 1.19)
Deep vein thrombosis - broad	Vaccinated with BNT162b2	December	184,519	14,132	48	41	1.17 (0.88 to 1.55)
Deep vein thrombosis - broad	Vaccinated with BNT162b2	January	821,952	62,905	176	155.9	1.13 (0.97 to 1.31)
Deep vein thrombosis - broad	Vaccinated with BNT162b2	February	634,702	40,831	70	70.4	0.99 (0.79 to 1.26)
Deep vein thrombosis - narrow	Vaccinated with ChAdOx1	January	500,896	38,291	99	94.6	1.05 (0.86 to 1.27)
Deep vein thrombosis - narrow	Vaccinated with ChAdOx1	February	1,057,960	72,347	119	132.5	0.90 (0.75 to 1.07)
Deep vein thrombosis - narrow	Vaccinated with BNT162b2	December	184,577	14,137	38	38.9	0.98 (0.71 to 1.34)
Deep vein thrombosis - narrow	Vaccinated with BNT162b2	January	822,272	62,930	156	146.8	1.06 (0.91 to 1.24)
Deep vein thrombosis - narrow	Vaccinated with BNT162b2	February	634,960	40,848	58	64.8	0.90 (0.69 to 1.16)
Deep vein thrombosis broad with thrombocytopenia 42 days pre to 14 days post	Vaccinated with ChAdOx1	February	1,060,631	72,536	5	3.9	1.27 (0.53 to 3.04)

Hemorrhagic stroke	Vaccinated with ChAdOx1	January	502,160	38,389	23	17.7	1.30 (0.86 to 1.96)
Hemorrhagic stroke	Vaccinated with ChAdOx1	February	1,060,241	72,509	22	23.5	0.94 (0.62 to 1.42)
Hemorrhagic stroke	Vaccinated with BNT162b2	December	184,976	14,169	9	7.7	1.17 (0.61 to 2.25)
Hemorrhagic stroke	Vaccinated with BNT162b2	January	823,977	63,066	20	27.6	0.72 (0.47 to 1.12)
Hemorrhagic stroke	Vaccinated with BNT162b2	February	636,384	40,939	9	11.4	0.79 (0.41 to 1.52)
Immune thrombocytopenia	Vaccinated with ChAdOx1	January	502,326	38,402	9	3.4	2.68 (1.39 to 5.15)
Immune thrombocytopenia	Vaccinated with ChAdOx1	February	1,060,537	72,529	9	5.2	1.73 (0.90 to 3.33)
Immune thrombocytopenia	Vaccinated with BNT162b2	January	824,130	63,078	14	5	2.81 (1.67 to 4.75)
Intestinal infarction	Vaccinated with ChAdOx1	January	502,337	38,403	9	6.2	1.46 (0.76 to 2.81)
Intestinal infarction	Vaccinated with BNT162b2	January	824,161	63,080	12	9.2	1.31 (0.74 to 2.30)
Ischemic stroke	Vaccinated with ChAdOx1	January	501,803	38,361	37	43.1	0.86 (0.62 to 1.18)
Ischemic stroke	Vaccinated with ChAdOx1	February	1,059,837	72,479	34	49.6	0.69 (0.49 to 0.96)
Ischemic stroke	Vaccinated with BNT162b2	December	184,824	14,157	26	19.9	1.31 (0.89 to 1.92)
Ischemic stroke	Vaccinated with BNT162b2	January	823,540	63,031	68	66.4	1.02 (0.81 to 1.30)
Ischemic stroke	Vaccinated with BNT162b2	February	636,189	40,926	26	22	1.18 (0.81 to 1.74)
Myocardial infarction	Vaccinated with ChAdOx1	January	500,165	38,233	140	164.6	0.85 (0.72 to 1.00)

Myocardial infarction	Vaccinated with ChAdOx1	February	1,056,556	72,245	198	229	0.86 (0.75 to 0.99)
Myocardial infarction	Vaccinated with BNT162b2	December	184,255	14,112	49	69.3	0.71 (0.53 to 0.94)
Myocardial infarction	Vaccinated with BNT162b2	January	821,182	62,846	196	252.8	0.78 (0.67 to 0.89)
Myocardial infarction	Vaccinated with BNT162b2	February	633,568	40,760	110	110.1	1.00 (0.83 to 1.20)
Myocardial infarction or ischemic stroke	Vaccinated with ChAdOx1	January	499,333	38,168	170	206.2	0.82 (0.71 to 0.96)
Myocardial infarction or ischemic stroke	Vaccinated with ChAdOx1	February	1,055,276	72,154	226	276.8	0.82 (0.72 to 0.93)
Myocardial infarction or ischemic stroke	Vaccinated with BNT162b2	December	183,921	14,086	73	88.5	0.82 (0.66 to 1.04)
Myocardial infarction or ischemic stroke	Vaccinated with BNT162b2	January	820,110	62,762	256	317	0.81 (0.71 to 0.91)
Myocardial infarction or ischemic stroke	Vaccinated with BNT162b2	February	632,863	40,715	129	131.2	0.98 (0.83 to 1.17)
Myocardial infarction or ischemic stroke with thrombocytopenia 42 days pre to 14 days post	Vaccinated with ChAdOx1	January	502,376	38,406	5	3.3	1.51 (0.63 to 3.63)
Myocardial infarction or ischemic stroke with thrombocytopenia 42 days pre to 14 days post	Vaccinated with ChAdOx1	February	1,060,624	72,535	5	3.1	1.63 (0.68 to 3.92)
Platelet disorder	Vaccinated with ChAdOx1	January	501,278	38,320	80	33.7	2.37 (1.91 to 2.96)
Platelet disorder	Vaccinated with ChAdOx1	February	1,058,821	72,404	109	49.1	2.22 (1.84 to 2.68)
Platelet disorder	Vaccinated with BNT162b2	December	184,637	14,143	20	13	1.54 (1.00 to 2.39)
Platelet disorder	Vaccinated with BNT162b2	January	822,623	62,959	110	51.2	2.15 (1.78 to 2.59)
Platelet disorder	Vaccinated with BNT162b2	February	635,605	40,885	42	23.7	1.77 (1.31 to 2.40)

Portal vein thrombosis	Vaccinated with ChAdOx1	February	1,060,619	72,535	5	3.3	1.53 (0.64 to 3.68)
Pulmonary embolism	Vaccinated with ChAdOx1	January	500,837	38,285	111	83.6	1.33 (1.10 to 1.60)
Pulmonary embolism	Vaccinated with ChAdOx1	February	1,057,749	72,331	141	118	1.19 (1.01 to 1.41)
Pulmonary embolism	Vaccinated with BNT162b2	December	184,573	14,137	31	32.9	0.94 (0.66 to 1.34)
Pulmonary embolism	Vaccinated with BNT162b2	January	822,279	62,931	159	126.8	1.25 (1.07 to 1.46)
Pulmonary embolism	Vaccinated with BNT162b2	February	634,850	40,840	68	56.1	1.21 (0.96 to 1.54)
Pulmonary embolism with thrombocytopenia 42 days pre to 14 days post	Vaccinated with BNT162b2	January	824,238	63,086	5	3.6	1.37 (0.57 to 3.30)
Splanchnic Vein Thrombosis	Vaccinated with ChAdOx1	February	1,060,615	72,535	5	3.9	1.28 (0.53 to 3.07)
Stroke	Vaccinated with ChAdOx1	January	499,555	38,185	201	179.2	1.12 (0.98 to 1.29)
Stroke	Vaccinated with ChAdOx1	February	1,056,990	72,274	209	212.1	0.99 (0.86 to 1.13)
Stroke	Vaccinated with BNT162b2	December	184,059	14,096	89	81.5	1.09 (0.89 to 1.34)
Stroke	Vaccinated with BNT162b2	January	820,899	62,823	250	276.1	0.91 (0.80 to 1.02)
Stroke	Vaccinated with BNT162b2	February	634,578	40,821	116	95.1	1.22 (1.02 to 1.46)
Stroke with thrombocytopenia 42 days pre to 14 days post	Vaccinated with BNT162b2	January	824,233	63,086	7	4.4	1.61 (0.77 to 3.37)
Thrombocytopenia	Vaccinated with ChAdOx1	January	491,132	37,523	722	564.8	1.28 (1.19 to 1.38)
Thrombocytopenia	Vaccinated with ChAdOx1	February	1,046,181	71,473	908	746.5	1.22 (1.14 to 1.30)

Thrombocytopenia	Vaccinated with BNT162b2	December	180,475	13,819	170	242.4	0.70 (0.60 to 0.82)
Thrombocytopenia	Vaccinated with BNT162b2	January	808,029	61,815	897	875.2	1.02 (0.96 to 1.09)
Thrombocytopenia	Vaccinated with BNT162b2	February	628,928	40,433	389	355.1	1.10 (0.99 to 1.21)
Thrombocytopenic purpura	Vaccinated with ChAdOx1	January	502,392	38,407	7	3	2.32 (1.11 to 4.87)
Thrombocytopenic purpura	Vaccinated with ChAdOx1	February	1,060,648	72,537	5	4.7	1.07 (0.45 to 2.58)
Thrombocytopenic purpura	Vaccinated with BNT162b2	January	824,225	63,085	5	4.5	1.10 (0.46 to 2.65)
Venous thromboembolism - broad	Vaccinated with ChAdOx1	January	499,197	38,157	216	176.9	1.22 (1.07 to 1.40)
Venous thromboembolism - broad	Vaccinated with ChAdOx1	February	1,054,809	72,122	275	249.1	1.10 (0.98 to 1.24)
Venous thromboembolism - broad	Vaccinated with BNT162b2	December	184,054	14,096	78	71.2	1.09 (0.88 to 1.37)
Venous thromboembolism - broad	Vaccinated with BNT162b2	January	820,096	62,758	320	271.7	1.18 (1.06 to 1.31)
Venous thromboembolism - broad	Vaccinated with BNT162b2	February	633,074	40,726	130	120.3	1.08 (0.91 to 1.28)
Venous thromboembolism - narrow	Vaccinated with ChAdOx1	January	499,419	38,175	196	171.4	1.14 (0.99 to 1.32)
Venous thromboembolism - narrow	Vaccinated with ChAdOx1	February	1,055,248	72,154	251	239.3	1.05 (0.93 to 1.19)
Venous thromboembolism - narrow	Vaccinated with BNT162b2	December	184,112	14,100	68	69.2	0.98 (0.78 to 1.25)
Venous thromboembolism - narrow	Vaccinated with BNT162b2	January	820,420	62,783	301	263	1.14 (1.02 to 1.28)
Venous thromboembolism - narrow	Vaccinated with BNT162b2	February	633,335	40,743	118	115	1.03 (0.86 to 1.23)

Venous thromboembolism broad with thrombocytopenia 10 days pre to 10 days post	Vaccinated with ChAdOx1	February	1,060,628	72,536	5	3.6	1.39 (0.58 to 3.33)
Venous thromboembolism broad with thrombocytopenia 42 days pre to 14 days post	Vaccinated with ChAdOx1	January	502,352	38,404	6	5.4	1.11 (0.50 to 2.47)
Venous thromboembolism broad with thrombocytopenia 42 days pre to 14 days post	Vaccinated with ChAdOx1	February	1,060,591	72,533	8	6.6	1.22 (0.61 to 2.44)
Venous thromboembolism broad with thrombocytopenia 42 days pre to 14 days post	Vaccinated with BNT162b2	January	824,171	63,081	7	8.1	0.86 (0.41 to 1.81)
Venous thromboembolism narrow with thrombocytopenia 42 days pre to 14 days post	Vaccinated with ChAdOx1	January	502,353	38,404	6	5.3	1.14 (0.51 to 2.53)
Venous thromboembolism narrow with thrombocytopenia 42 days pre to 14 days post	Vaccinated with ChAdOx1	February	1,060,595	72,533	6	6.3	0.95 (0.43 to 2.11)
Venous thromboembolism narrow with thrombocytopenia 42 days pre to 14 days post	Vaccinated with BNT162b2	January	824,177	63,081	7	7.9	0.88 (0.42 to 1.85)

Results without requiring year of prior history

For each event of interest the number of persons contributing to the analysis from the target population, their person-years contributed, and the number of events observed for them are given. Their expected events are estimated using indirect standardisation to the general population, with expected events giving the number of events we would have expected to have seen if their outcome experience was the same as that of the general population. Standardised incidence ratios (SIRs) with 95% confidence intervals (CIs) were estimated. Events with less than 5 occurrences have been omitted for privacy reasons.

Event	Cohort	N	Person-years	Observed events	Expected events	SIR (95% CI)
Cerebral venous sinus thrombosis	Vaccinated with ChAdOx1	1,956,136	124,569	5	2.2	2.32 (0.97 to 5.58)
Deep vein thrombosis - broad	Vaccinated with ChAdOx1	1,950,188	124,172	305	275.8	1.11 (0.99 to 1.24)
Deep vein thrombosis - broad	Vaccinated with BNT162b2	1,726,968	123,253	312	289.5	1.08 (0.96 to 1.20)
Deep vein thrombosis - broad	SARS-CoV-2 PCR positive test	298,832	40,538	143	55.1	2.60 (2.20 to 3.06)
Deep vein thrombosis - narrow	Vaccinated with ChAdOx1	1,950,982	124,225	253	258	0.98 (0.87 to 1.11)
Deep vein thrombosis - narrow	Vaccinated with BNT162b2	1,727,622	123,301	268	272.3	0.98 (0.87 to 1.11)
Deep vein thrombosis - narrow	SARS-CoV-2 PCR positive test	298,901	40,549	125	50.8	2.46 (2.07 to 2.93)
Deep vein thrombosis broad with thrombocytopenia 10 days pre to 10 days post	Vaccinated with ChAdOx1	1,956,124	124,567	9	4.6	1.96 (1.02 to 3.77)
Deep vein thrombosis broad with thrombocytopenia 42 days pre to 14 days post	Vaccinated with ChAdOx1	1,956,087	124,564	12	8	1.51 (0.86 to 2.65)
Deep vein thrombosis broad with thrombocytopenia 42 days pre to 14 days post	Vaccinated with BNT162b2	1,731,862	123,610	5	8.4	0.59 (0.25 to 1.42)
Deep vein thrombosis narrow with thrombocytopenia 10 days pre to 10 days post	Vaccinated with ChAdOx1	1,956,131	124,568	6	4.3	1.39 (0.62 to 3.09)

Deep vein thrombosis narrow with thrombocytopenia 42 days pre to 14 days post	Vaccinated with ChAdOx1	1,956,096	124,565	9	7.6	1.19 (0.62 to 2.29)
Deep vein thrombosis narrow with thrombocytopenia 42 days pre to 14 days post	Vaccinated with BNT162b2	1,731,870	123,610	5	8.1	0.62 (0.26 to 1.48)
Hemorrhagic stroke	Vaccinated with ChAdOx1	1,955,323	124,513	51	47.2	1.08 (0.82 to 1.42)
Hemorrhagic stroke	Vaccinated with BNT162b2	1,731,304	123,569	38	51.3	0.74 (0.54 to 1.02)
Hemorrhagic stroke	SARS-CoV-2 PCR positive test	299,252	40,605	11	8.5	1.29 (0.71 to 2.33)
Immune thrombocytopenia	Vaccinated with ChAdOx1	1,955,913	124,552	18	9.9	1.82 (1.14 to 2.88)
Immune thrombocytopenia	Vaccinated with BNT162b2	1,731,680	123,596	16	9.5	1.68 (1.03 to 2.75)
Immune thrombocytopenia	SARS-CoV-2 PCR positive test	299,300	40,614	5	1.8	2.71 (1.13 to 6.52)
Intestinal infarction	Vaccinated with ChAdOx1	1,955,897	124,551	16	15.8	1.01 (0.62 to 1.66)
Intestinal infarction	Vaccinated with BNT162b2	1,731,725	123,600	18	16	1.12 (0.71 to 1.78)
Ischemic stroke	Vaccinated with ChAdOx1	1,954,444	124,451	83	103.1	0.81 (0.65 to 1.00)
Ischemic stroke	Vaccinated with BNT162b2	1,730,486	123,507	124	115.7	1.07 (0.90 to 1.28)
Ischemic stroke	SARS-CoV-2 PCR positive test	299,225	40,603	13	12.6	1.03 (0.60 to 1.77)
Myocardial infarction	Vaccinated with ChAdOx1	1,948,615	124,056	368	440.2	0.84 (0.75 to 0.93)
Myocardial infarction	Vaccinated with BNT162b2	1,724,692	123,097	375	459	0.82 (0.74 to 0.90)
Myocardial infarction	SARS-CoV-2 PCR positive test	298,757	40,530	79	67.2	1.17 (0.94 to 1.46)

Myocardial infarction or ischemic stroke	Vaccinated with ChAdOx1	1,946,125	123,887	438	539.6	0.81 (0.74 to 0.89)
Myocardial infarction or ischemic stroke	Vaccinated with BNT162b2	1,722,509	122,937	481	570.7	0.84 (0.77 to 0.92)
Myocardial infarction or ischemic stroke	SARS-CoV-2 PCR positive test	298,589	40,506	88	79.4	1.11 (0.90 to 1.37)
Myocardial infarction or ischemic stroke with thrombocytopenia 10 days pre to 10 days post	Vaccinated with ChAdOx1	1,956,120	124,567	5	3.6	1.39 (0.58 to 3.34)
Myocardial infarction or ischemic stroke with thrombocytopenia 10 days pre to 10 days post	Vaccinated with BNT162b2	1,731,873	123,611	5	4.5	1.12 (0.47 to 2.69)
Myocardial infarction or ischemic stroke with thrombocytopenia 42 days pre to 14 days post	Vaccinated with ChAdOx1	1,956,063	124,563	10	7.2	1.39 (0.75 to 2.58)
Myocardial infarction or ischemic stroke with thrombocytopenia 42 days pre to 14 days post	Vaccinated with BNT162b2	1,731,829	123,607	7	8.8	0.80 (0.38 to 1.67)
Platelet disorder	Vaccinated with ChAdOx1	1,952,742	124,328	216	94.4	2.29 (2.00 to 2.62)
Platelet disorder	Vaccinated with BNT162b2	1,728,759	123,378	184	95.6	1.93 (1.67 to 2.22)
Platelet disorder	SARS-CoV-2 PCR positive test	299,047	40,574	57	16.8	3.40 (2.62 to 4.41)
Portal vein thrombosis	Vaccinated with ChAdOx1	1,956,077	124,565	8	5.7	1.41 (0.71 to 2.82)
Pulmonary embolism	Vaccinated with ChAdOx1	1,950,701	124,202	281	225.9	1.24 (1.11 to 1.40)
Pulmonary embolism	Vaccinated with BNT162b2	1,727,494	123,293	282	231.3	1.22 (1.09 to 1.37)
Pulmonary embolism	SARS-CoV-2 PCR positive test	298,910	40,513	547	37	14.77 (13.58 to 16.06)
Pulmonary embolism with thrombocytopenia 42 days pre to 14 days post	Vaccinated with ChAdOx1	1,956,118	124,567	6	5.9	1.02 (0.46 to 2.26)
Pulmonary embolism with thrombocytopenia 42 days pre to 14 days post	Vaccinated with BNT162b2	1,731,900	123,612	7	6.1	1.15 (0.55 to 2.40)

Pulmonary embolism with thrombocytopenia 42 days pre to 14 days post	SARS-CoV-2 PCR positive test	299,333	40,618	6	0.8	7.96 (3.58 to 17.71)
Splanchnic Vein Thrombosis	Vaccinated with ChAdOx1	1,956,072	124,564	9	6.9	1.31 (0.68 to 2.52)
Stroke	Vaccinated with ChAdOx1	1,948,412	124,026	481	443	1.09 (0.99 to 1.19)
Stroke	Vaccinated with BNT162b2	1,725,125	123,110	482	495.6	0.97 (0.89 to 1.06)
Stroke	SARS-CoV-2 PCR positive test	298,834	40,547	66	56.9	1.16 (0.91 to 1.48)
Stroke with thrombocytopenia 10 days pre to 10 days post	Vaccinated with ChAdOx1	1,956,146	124,568	6	3.2	1.88 (0.85 to 4.19)
Stroke with thrombocytopenia 42 days pre to 14 days post	Vaccinated with ChAdOx1	1,956,114	124,566	7	6.5	1.07 (0.51 to 2.25)
Stroke with thrombocytopenia 42 days pre to 14 days post	Vaccinated with BNT162b2	1,731,882	123,611	8	7.7	1.04 (0.52 to 2.09)
Thrombocytopenia	Vaccinated with ChAdOx1	1,927,116	122,484	1,865	1,517.30	1.23 (1.17 to 1.29)
Thrombocytopenia	Vaccinated with BNT162b2	1,702,494	121,405	1,548	1,624.40	0.95 (0.91 to 1.00)
Thrombocytopenia	SARS-CoV-2 PCR positive test	297,122	40,310	254	266.7	0.95 (0.84 to 1.08)
Thrombocytopenic purpura	Vaccinated with ChAdOx1	1,956,098	124,565	12	9.2	1.31 (0.74 to 2.31)
Thrombocytopenic purpura	Vaccinated with BNT162b2	1,731,847	123,609	6	8.9	0.68 (0.30 to 1.51)
Venous thromboembolism - broad	Vaccinated with ChAdOx1	1,945,125	123,830	558	479.9	1.16 (1.07 to 1.26)
Venous thromboembolism - broad	Vaccinated with BNT162b2	1,722,829	122,953	569	499.3	1.14 (1.05 to 1.24)
Venous thromboembolism - broad	SARS-CoV-2 PCR positive test	298,453	40,439	664	87.3	7.61 (7.05 to 8.21)

Venous thromboembolism - narrow	Vaccinated with ChAdOx1	1,945,919	123,883	508	463.2	1.10 (1.01 to 1.20)
Venous thromboembolism - narrow	Vaccinated with BNT162b2	1,723,490	123,001	526	482.9	1.09 (1.00 to 1.19)
Venous thromboembolism - narrow	SARS-CoV-2 PCR positive test	298,521	40,450	646	83.2	7.76 (7.19 to 8.39)
Venous thromboembolism broad with thrombocytopenia 10 days pre to 10 days post	Vaccinated with ChAdOx1	1,956,082	124,564	12	7.2	1.66 (0.94 to 2.92)
Venous thromboembolism broad with thrombocytopenia 10 days pre to 10 days post	Vaccinated with BNT162b2	1,731,858	123,609	7	7.6	0.92 (0.44 to 1.93)
Venous thromboembolism broad with thrombocytopenia 42 days pre to 14 days post	Vaccinated with ChAdOx1	1,956,004	124,558	17	13.2	1.29 (0.80 to 2.07)
Venous thromboembolism broad with thrombocytopenia 42 days pre to 14 days post	Vaccinated with BNT162b2	1,731,794	123,604	11	13.9	0.79 (0.44 to 1.42)
Venous thromboembolism broad with thrombocytopenia 42 days pre to 14 days post	SARS-CoV-2 PCR positive test	299,324	40,617	6	1.7	3.46 (1.55 to 7.69)
Venous thromboembolism narrow with thrombocytopenia 10 days pre to 10 days post	Vaccinated with ChAdOx1	1,956,088	124,564	9	7	1.28 (0.67 to 2.47)
Venous thromboembolism narrow with thrombocytopenia 10 days pre to 10 days post	Vaccinated with BNT162b2	1,731,863	123,610	7	7.4	0.94 (0.45 to 1.98)
Venous thromboembolism narrow with thrombocytopenia 42 days pre to 14 days post	Vaccinated with ChAdOx1	1,956,011	124,559	14	12.9	1.09 (0.64 to 1.83)
Venous thromboembolism narrow with thrombocytopenia 42 days pre to 14 days post	Vaccinated with BNT162b2	1,731,801	123,605	11	13.6	0.81 (0.45 to 1.46)
Venous thromboembolism narrow with thrombocytopenia 42 days pre to 14 days post	SARS-CoV-2 PCR positive test	299,324	40,617	6	1.7	3.59 (1.61 to 8.00)

Results with general population identified as of 1st December 2017

For each event of interest the number of persons contributing to the analysis from the target population, their person-years contributed, and the number of events observed for them are given. Their expected events are estimated using indirect standardisation to the general population, with expected events giving the number of events we would have expected to have seen if their outcome experience was the same as that of the general population. Standardised incidence ratios (SIRs) with 95% confidence intervals (CIs) were estimated. Events with less than 5 occurrences have been omitted for privacy reasons. *Cerebral venous sinus thrombosis is reported without the requirement for a year of prior history as less than 5 events were seen when this restriction was imposed.

Event	Cohort	N	Person-years	Observed events	Expected events	SIR (95% CI)
Cerebral venous sinus thrombosis*	Vaccinated with ChAdOx1	1,956,136	124,569	5	1.8	2.70 (1.13 to 6.49)
Deep vein thrombosis - broad	Vaccinated with ChAdOx1	1,862,896	118,757	275	239.4	1.15 (1.02 to 1.29)
Deep vein thrombosis - broad	Vaccinated with BNT162b2	1,656,235	118,297	296	249.7	1.19 (1.06 to 1.33)
Deep vein thrombosis - broad	SARS-CoV-2 PCR positive test	298,707	40,517	143	46.9	3.05 (2.59 to 3.59)
Deep vein thrombosis - narrow	Vaccinated with ChAdOx1	1,863,668	118,809	226	223.2	1.01 (0.89 to 1.15)
Deep vein thrombosis - narrow	Vaccinated with BNT162b2	1,656,875	118,344	254	234	1.09 (0.96 to 1.23)
Deep vein thrombosis - narrow	SARS-CoV-2 PCR positive test	298,776	40,528	125	43	2.90 (2.44 to 3.46)
Deep vein thrombosis broad with thrombocytopenia 10 days pre to 10 days post	Vaccinated with ChAdOx1	1,868,584	119,135	6	3.9	1.55 (0.70 to 3.45)
Deep vein thrombosis broad with thrombocytopenia 42 days pre to 14 days post	Vaccinated with ChAdOx1	1,868,547	119,132	9	6.9	1.30 (0.68 to 2.51)
Deep vein thrombosis narrow with thrombocytopenia 42 days pre to 14 days post	Vaccinated with ChAdOx1	1,868,554	119,133	7	6.5	1.07 (0.51 to 2.25)
Hemorrhagic stroke	Vaccinated with ChAdOx1	1,867,822	119,084	45	40.9	1.10 (0.82 to 1.47)

Hemorrhagic stroke	Vaccinated with BNT162b2	1,660,431	118,603	38	44.3	0.86 (0.62 to 1.18)
Hemorrhagic stroke	SARS-CoV-2 PCR positive test	299,127	40,584	11	7.5	1.47 (0.82 to 2.66)
Immune thrombocytopenia	Vaccinated with ChAdOx1	1,868,376	119,120	18	8.4	2.15 (1.35 to 3.41)
Immune thrombocytopenia	Vaccinated with BNT162b2	1,660,786	118,628	15	8	1.87 (1.13 to 3.11)
Immune thrombocytopenia	SARS-CoV-2 PCR positive test	299,175	40,593	5	1.5	3.23 (1.35 to 7.77)
Intestinal infarction	Vaccinated with ChAdOx1	1,868,365	119,120	13	14.3	0.91 (0.53 to 1.56)
Intestinal infarction	Vaccinated with BNT162b2	1,660,825	118,631	17	14.6	1.16 (0.72 to 1.87)
Ischemic stroke	Vaccinated with ChAdOx1	1,867,000	119,025	72	91.2	0.79 (0.63 to 0.99)
Ischemic stroke	Vaccinated with BNT162b2	1,659,635	118,542	120	102.6	1.17 (0.98 to 1.40)
Ischemic stroke	SARS-CoV-2 PCR positive test	299,100	40,582	13	11.4	1.14 (0.66 to 1.96)
Myocardial infarction	Vaccinated with ChAdOx1	1,861,365	118,643	347	391.6	0.89 (0.80 to 0.98)
Myocardial infarction	Vaccinated with BNT162b2	1,654,037	118,145	356	409.8	0.87 (0.78 to 0.96)
Myocardial infarction	SARS-CoV-2 PCR positive test	298,632	40,509	79	61.1	1.29 (1.04 to 1.61)
Myocardial infarction or ischemic stroke	Vaccinated with ChAdOx1	1,858,974	118,481	406	479.5	0.85 (0.77 to 0.93)
Myocardial infarction or ischemic stroke	Vaccinated with BNT162b2	1,651,903	117,990	458	508.9	0.90 (0.82 to 0.99)
Myocardial infarction or ischemic stroke	SARS-CoV-2 PCR positive test	298,464	40,485	88	72.1	1.22 (0.99 to 1.50)

Myocardial infarction or ischemic stroke with thrombocytopenia 10 days pre to 10 days post	Vaccinated with ChAdOx1	1,868,580	119,135	5	3	1.66 (0.69 to 3.99)
Myocardial infarction or ischemic stroke with thrombocytopenia 42 days pre to 14 days post	Vaccinated with ChAdOx1	1,868,524	119,131	10	6.2	1.62 (0.87 to 3.02)
Myocardial infarction or ischemic stroke with thrombocytopenia 42 days pre to 14 days post	Vaccinated with BNT162b2	1,660,931	118,639	6	7.8	0.77 (0.35 to 1.71)
Platelet disorder	Vaccinated with ChAdOx1	1,865,323	118,905	198	81.2	2.44 (2.12 to 2.80)
Platelet disorder	Vaccinated with BNT162b2	1,657,943	118,416	174	82	2.12 (1.83 to 2.46)
Platelet disorder	SARS-CoV-2 PCR positive test	298,922	40,552	57	14	4.08 (3.14 to 5.28)
Portal vein thrombosis	Vaccinated with ChAdOx1	1,868,539	119,133	8	5.2	1.55 (0.77 to 3.09)
Pulmonary embolism	Vaccinated with ChAdOx1	1,863,403	118,787	259	198.7	1.30 (1.15 to 1.47)
Pulmonary embolism	Vaccinated with BNT162b2	1,656,755	118,336	261	202.8	1.29 (1.14 to 1.45)
Pulmonary embolism	SARS-CoV-2 PCR positive test	298,786	40,491	547	32	17.09 (15.72 to 18.58)
Pulmonary embolism with thrombocytopenia 42 days pre to 14 days post	Vaccinated with ChAdOx1	1,868,576	119,134	6	5.2	1.16 (0.52 to 2.58)
Pulmonary embolism with thrombocytopenia 42 days pre to 14 days post	Vaccinated with BNT162b2	1,660,999	118,644	7	5.5	1.27 (0.60 to 2.65)
Pulmonary embolism with thrombocytopenia 42 days pre to 14 days post	SARS-CoV-2 PCR positive test	299,208	40,596	6	0.7	9.05 (4.07 to 20.14)
Splanchnic Vein Thrombosis	Vaccinated with ChAdOx1	1,868,536	119,132	9	6.2	1.46 (0.76 to 2.80)
Stroke	Vaccinated with ChAdOx1	1,861,358	118,629	413	385.8	1.07 (0.97 to 1.18)
Stroke	Vaccinated with BNT162b2	1,654,569	118,167	457	429.2	1.06 (0.97 to 1.17)

Stroke	SARS-CoV-2 PCR positive test	298,709	40,525	65	50.4	1.29 (1.01 to 1.64)
Stroke with thrombocytopenia 10 days pre to 10 days post	Vaccinated with ChAdOx1	1,868,605	119,136	6	2.6	2.32 (1.04 to 5.16)
Stroke with thrombocytopenia 42 days pre to 14 days post	Vaccinated with ChAdOx1	1,868,573	119,134	6	5.5	1.09 (0.49 to 2.43)
Stroke with thrombocytopenia 42 days pre to 14 days post	Vaccinated with BNT162b2	1,660,982	118,643	8	6.5	1.24 (0.62 to 2.47)
Thrombocytopenia	Vaccinated with ChAdOx1	1,840,495	117,121	1,707	1,281.00	1.33 (1.27 to 1.40)
Thrombocytopenia	Vaccinated with BNT162b2	1,632,328	116,491	1,462	1,372.60	1.07 (1.01 to 1.12)
Thrombocytopenia	SARS-CoV-2 PCR positive test	296,999	40,289	254	218.9	1.16 (1.03 to 1.31)
Thrombocytopenic purpura	Vaccinated with ChAdOx1	1,868,562	119,134	12	7.5	1.59 (0.90 to 2.80)
Thrombocytopenic purpura	Vaccinated with BNT162b2	1,660,955	118,641	5	7.3	0.68 (0.28 to 1.64)
Venous thromboembolism - broad	Vaccinated with ChAdOx1	1,858,064	118,431	508	419.1	1.21 (1.11 to 1.32)
Venous thromboembolism - broad	Vaccinated with BNT162b2	1,652,244	118,007	532	433.9	1.23 (1.13 to 1.33)
Venous thromboembolism - broad	SARS-CoV-2 PCR positive test	298,329	40,418	664	74.8	8.88 (8.23 to 9.58)
Venous thromboembolism - narrow	Vaccinated with ChAdOx1	1,858,837	118,483	461	403.9	1.14 (1.04 to 1.25)
Venous thromboembolism - narrow	Vaccinated with BNT162b2	1,652,892	118,054	491	419	1.17 (1.07 to 1.28)
Venous thromboembolism - narrow	SARS-CoV-2 PCR positive test	298,397	40,429	646	71.1	9.09 (8.42 to 9.82)
Venous thromboembolism broad with thrombocytopenia 10 days pre to 10 days post	Vaccinated with ChAdOx1	1,868,543	119,132	9	6.2	1.44 (0.75 to 2.77)

Venous thromboembolism broad with thrombocytopenia 10 days pre to 10 days post	Vaccinated with BNT162b2	1,660,959	118,641	6	6.7	0.90 (0.41 to 2.01)
Venous thromboembolism broad with thrombocytopenia 42 days pre to 14 days post	Vaccinated with ChAdOx1	1,868,467	119,126	14	11.6	1.21 (0.72 to 2.04)
Venous thromboembolism broad with thrombocytopenia 42 days pre to 14 days post	Vaccinated with BNT162b2	1,660,896	118,636	10	12.4	0.81 (0.43 to 1.50)
Venous thromboembolism broad with thrombocytopenia 42 days pre to 14 days post	SARS-CoV-2 PCR positive test	299,199	40,595	6	1.5	3.93 (1.77 to 8.76)
Venous thromboembolism narrow with thrombocytopenia 10 days pre to 10 days post	Vaccinated with ChAdOx1	1,868,547	119,132	7	6	1.16 (0.56 to 2.44)
Venous thromboembolism narrow with thrombocytopenia 10 days pre to 10 days post	Vaccinated with BNT162b2	1,660,964	118,641	6	6.5	0.93 (0.42 to 2.06)
Venous thromboembolism narrow with thrombocytopenia 42 days pre to 14 days post	Vaccinated with ChAdOx1	1,868,472	119,127	12	11.3	1.07 (0.61 to 1.88)
Venous thromboembolism narrow with thrombocytopenia 42 days pre to 14 days post	Vaccinated with BNT162b2	1,660,903	118,637	10	12.1	0.83 (0.44 to 1.54)
Venous thromboembolism narrow with thrombocytopenia 42 days pre to 14 days post	SARS-CoV-2 PCR positive test	299,199	40,595	6	1.5	4.11 (1.85 to 9.14)

Incidence rate ratios (IRRs) and 95% confidence intervals for pulmonary embolism stratified by age, sex, and calendar month

Patient profiles: pulmonary embolism

The characteristics of persons with pulmonary embolism used for the primary analyses. *Conditions of interest: autoimmune disease, antiphospholipid syndrome, thrombophilia, asthma, atrial fibrillation, malignant neoplastic disease, diabetes mellitus, obesity, or renal impairment. †Medications of interest included non-steroidal anti-inflammatory drugs, Cox2 inhibitors, systemic corticosteroids, hormonal contraceptives, tamoxifen, and sex hormones and modulators of the genital system

	General population	Vaccinated with ChAdOx1	Vaccinated with BNT162b2
N	7,414	281	282
Age	68 [56 to 77]	74 [67 to 79]	75 [66 to 82]
Age: 30 to 39	474 (6.4%)	<5	6 (2.1%)
Age: 40 to 49	735 (9.9%)	12 (4.3%)	14 (5.0%)
Age: 50 to 59	1,164 (15.7%)	30 (10.7%)	23 (8.2%)
Age: 60 to 69	1,666 (22.5%)	49 (17.4%)	51 (18.1%)
Age: 70 to 79	1,918 (25.9%)	119 (42.3%)	89 (31.6%)
Age: 80 or older	1,457 (19.7%)	69 (24.6%)	99 (35.1%)
Sex: Male	3,543 (47.8%)	138 (49.1%)	135 (47.9%)
Years of prior observation time	14.9 [7.9 to 17.6]	17.8 [6.0 to 32.5]	21.5 [8.7 to 34.9]
Comorbidities			
Autoimmune disease	325 (4.4%)	13 (4.6%)	18 (6.4%)
Antiphospholipid syndrome	14 (0.2%)	0 (0.0%)	0 (0.0%)
Thrombophilia	36 (0.5%)	0 (0.0%)	0 (0.0%)
Asthma	1,137 (15.3%)	43 (15.3%)	39 (13.8%)
Atrial fibrillation	302 (4.1%)	19 (6.8%)	14 (5.0%)
Malignant neoplastic disease	1,533 (20.7%)	91 (32.4%)	94 (33.3%)
Diabetes mellitus	974 (13.1%)	51 (18.1%)	46 (16.3%)
Obesity	556 (7.5%)	23 (8.2%)	21 (7.4%)
Heart disease	1,382 (18.6%)	73 (26.0%)	64 (22.7%)
Hypertensive disorder	2,832 (38.2%)	120 (42.7%)	129 (45.7%)
Renal impairment	1,131 (15.3%)	63 (22.4%)	71 (25.2%)

COPD	674 (9.1%)	31 (11.0%)	33 (11.7%)
Dementia	176 (2.4%)	23 (8.2%)	11 (3.9%)
Medication use (183 days prior to four days prior)			
Non-steroidal anti-inflammatory drugs	4,302 (58.0%)	87 (31.0%)	77 (27.3%)
Cox2 inhibitors	42 (0.6%)	0 (0.0%)	<5
Systemic corticosteroids	2,001 (27.0%)	43 (15.3%)	34 (12.1%)
Antithrombotic and anticoagulant therapies	1,555 (21.0%)	35 (12.5%)	32 (11.3%)
Lipid modifying agents	890 (12.0%)	29 (10.3%)	23 (8.2%)
Antineoplastic and immunomodulating agents	387 (5.2%)	11 (3.9%)	12 (4.3%)
Hormonal contraceptives for systemic use	158 (2.1%)	<5	6 (2.1%)
Tamoxifen	39 (0.5%)	<5	<5
Sex hormones and modulators of the genital system	295 (4.0%)	9 (3.2%)	9 (3.2%)
One or more condition of interest*	3,388 (45.7%)	165 (58.7%)	176 (62.4%)
One or more medication of interest [†]	4,746 (64.0%)	108 (38.4%)	100 (35.5%)
One or more condition/ medication of interest* [†]	5,745 (77.5%)	199 (70.8%)	207 (73.4%)

Incidence rate ratios (IRRs) and 95% confidence intervals for thrombocytopenia stratified by age, sex, and calendar month

Patient profiles: thrombocytopenia

The characteristics of persons with thrombocytopenia used for the primary analyses. *Conditions of interest: autoimmune disease, antiphospholipid syndrome, thrombophilia, asthma, atrial fibrillation, malignant neoplastic disease, diabetes mellitus, obesity, or renal impairment. †Medications of interest included non-steroidal anti-inflammatory drugs, Cox2 inhibitors, systemic corticosteroids, hormonal contraceptives, tamoxifen, and sex hormones and modulators of the genital system

	General population	Vaccinated with ChAdOx1	Vaccinated with BNT162b2
N	50,690	1,865	1,548
Age	67 [53 to 78]	73 [64 to 79]	78 [68 to 85]
Age: 30 to 39	4,604 (9.1%)	54 (2.9%)	31 (2.0%)
Age: 40 to 49	5,289 (10.4%)	101 (5.4%)	68 (4.4%)
Age: 50 to 59	7,994 (15.8%)	176 (9.4%)	129 (8.3%)
Age: 60 to 69	10,130 (20.0%)	379 (20.3%)	199 (12.9%)
Age: 70 to 79	11,963 (23.6%)	728 (39.0%)	431 (27.8%)
Age: 80 or older	10,710 (21.1%)	427 (22.9%)	690 (44.6%)
Sex: Male	31,064 (61.3%)	1,181 (63.3%)	1,022 (66.0%)
Years of prior observation time	14.4 [5.9 to 17.2]	16.9 [5.5 to 31.3]	22.1 [7.3 to 33.6]
Comorbidities			
Autoimmune disease	2,551 (5.0%)	134 (7.2%)	128 (8.3%)
Antiphospholipid syndrome	40 (0.1%)	5 (0.3%)	<5
Thrombophilia	73 (0.1%)	8 (0.4%)	6 (0.4%)
Asthma	5,755 (11.4%)	223 (12.0%)	170 (11.0%)
Atrial fibrillation	6,002 (11.8%)	341 (18.3%)	408 (26.4%)
Malignant neoplastic disease	8,691 (17.1%)	451 (24.2%)	441 (28.5%)
Diabetes mellitus	9,211 (18.2%)	542 (29.1%)	431 (27.8%)
Obesity	2,819 (5.6%)	169 (9.1%)	90 (5.8%)
Heart disease	14,636 (28.9%)	764 (41.0%)	765 (49.4%)
Hypertensive disorder	20,144 (39.7%)	990 (53.1%)	900 (58.1%)
Renal impairment	8,695 (17.2%)	457 (24.5%)	491 (31.7%)

COPD	3,023 (6.0%)	166 (8.9%)	139 (9.0%)
Dementia	1,421 (2.8%)	109 (5.8%)	58 (3.7%)
Medication use (183 days prior to four days prior)			
Non-steroidal anti-inflammatory drugs	27,424 (54.1%)	587 (31.5%)	543 (35.1%)
Cox2 inhibitors	293 (0.6%)	7 (0.4%)	6 (0.4%)
Systemic corticosteroids	13,729 (27.1%)	301 (16.1%)	266 (17.2%)
Antithrombotic and anticoagulant therapies	9,624 (19.0%)	226 (12.1%)	254 (16.4%)
Lipid modifying agents	8,093 (16.0%)	249 (13.4%)	248 (16.0%)
Antineoplastic and immunomodulating agents	2,793 (5.5%)	48 (2.6%)	47 (3.0%)
Hormonal contraceptives for systemic use	976 (1.9%)	12 (0.6%)	12 (0.8%)
Tamoxifen	137 (0.3%)	0 (0.0%)	<5
Sex hormones and modulators of the genital system	1,878 (3.7%)	36 (1.9%)	27 (1.7%)
One or more condition of interest*	25,148 (49.6%)	1,271 (68.2%)	1,160 (74.9%)
One or more medication of interest [†]	30,447 (60.1%)	670 (35.9%)	625 (40.4%)
One or more condition/ medication of interest* [†]	38,782 (76.5%)	1,448 (77.6%)	1,298 (83.9%)